Podcasts about enhertu

Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in cancer research, and this year was no exception. In this episode of "The Top Line," Fierce reporters take you inside the action at ASCO 2025. Zoey Becker shares the story behind Johnson & Johnson’s dramatic “Breathtaking” campaign, staged on the 99th floor of Chicago’s Willis Tower. Angus Liu breaks down phase 3 data on Enhertu from AstraZeneca and Daiichi Sankyo, while Gabrielle Masson overviews Bicara Therapeutics' investigational asset for head and neck squamous cell carcinoma. Plus, the team compares notes from the ASCO exhibit hall. To learn more about the topics in this episode: ASCO: AstraZeneca, Daiichi flex Enhertu's muscles in first-line breast cancer as they drop new phase 3 gastric cancer data 'Our data is resonating far more with the people that matter,' Bicara CEO says amid Merus race ASCO: J&J highlights Rybrevant-Lazcluze combo in 'Breathtaking Moments' lung cancer campaign high over Chicago skyline See omnystudio.com/listener for privacy information.

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featured five days of presentations and educational sessions on all types of cancer. Dr. Eleonora Teplinsky, a board-certified medical oncologist at the Valley-Mount Sinai Comprehensive Cancer Center in Paramus, NJ, summarizes the top breast cancer research. Listen to the episode to hear Dr. Teplinsky discuss: The SERENA-6 trial, which found that if metastatic hormone receptor-positive, HER2-negative breast cancer develops ESR1 mutations during first hormonal therapy treatment, switching to camizestrant from an aromatase inhibitor before the cancer grows improves outcomes. Results from the DESTINY-Breast09 trial showing that the combination of Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) and Perjeta (chemical name: pertuzumab) is a better first treatment for metastatic HER2-positive breast cancer than the current standard of THP chemo.  The ASCENT-04/KEYNOTE-D19 trial, which found that people with metastatic, PD-L1-positive, triple-negative breast cancer fared better with the combo of Trodelvy (chemical name: sacituzumab govitecan-hziy) and Keytruda (chemical name: pembrolizumab) as a first treatment compared to people who received chemotherapy and Keytruda.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Roche and Regeneron are both investing heavily in US manufacturing, with Roche committing $50 billion and Regeneron signing a $3 billion deal with Fujifilm. This move comes as Trump's tariffs threaten the industry. Meanwhile, Pfizer, Alnylam, and BridgeBio are competing in the market for ATTR-CM treatment, with Alnylam and BridgeBio vying for patients switching from Pfizer's tafamidis drug and all three companies seeking new patients.Novo Nordisk has filed for FDA approval of an oral weight loss pill, AstraZeneca and Daiichi Sankyo are pushing their drug Enhertu for frontline breast cancer treatment, and Gilead's Trodelvy in combination with Keytruda has shown promise in slowing disease progression in triple-negative breast cancer. Wacker Biotech is offering services for advanced therapies, while Tempest has recently laid off 80% of its workforce.The industry is facing regulatory challenges and economic uncertainty, with Trump's tariffs potentially impacting pharma companies. Lilly has promised to manufacture a weight-loss pill in the US following a phase III win, and Makary discusses rare disease approvals and public distrust in a new interview. Biotech's future may be more focused on American companies according to PitchBook.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Pfizer and Eli Lilly are considering reshoring manufacturing in the U.S. in response to President Trump's tariff threats. Biohaven faces setbacks in clinical trials, while Roche gains FDA approval for a stroke drug expansion. Startup Delphia aims to use a precision medicine approach to target cancer cells. Industry leaders will discuss orphan drug development at the World Orphan Drug Congress 2025. Other news includes Beigene's label expansion, AstraZeneca and Daiichi Sankyo's success with Enhertu in stomach cancer, and Atara's restructuring.

In today's episode, we had the pleasure of speaking with Aditya Bardia, MD, MPH, FASCO, about the FDA approval of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the treatment of adult patients with unresectable or metastatic, hormone receptor–positive, HER2-low or -ultralow breast cancer, as determined by an FDA-approved test, that has progressed on at least 1 endocrine therapy in the metastatic setting. Dr Bardia serves as a professor in the Department of Medicine in the Division of Hematology/Oncology and is the director of Translational Research Integration at the UCLA Health Jonsson Comprehensive Cancer Center. In our exclusive interview, Dr Bardia discussed the significance of this approval, findings from the pivotal DESTINY-Breast06 trial (NCT04494425), and what this new indication for T-DXd means for the future of HER2 testing in breast cancer.

Ozempic gains expanded approval; MS treatment gets Boxed Warning added to label; Monotherapy approval granted for treatment resistant depression Tx Spravato; Leqembi gains  maintenance regimen; Enhertu gains new Breast CA indication.  

In today's episode, we had the pleasure of speaking with David Gerber, MD, a professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center, a member of its Division of Hematology/Oncology, and co-director of Education and Training for the Harold C. Simmons Comprehensive Cancer Center in Dallas. In our exclusive interview, Dr Gerber discussed the evolving role of antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC), focusing on findings from key clinical trials. He highlighted results from the phase 3 TROPION-Lung01 trial (NCT04656652), which demonstrated a modest improvement in progression-free survival with datopotamab deruxtecan-dlnk (Datroway), a TROP2-directed ADC, compared with docetaxel in patients with previously treated advanced NSCLC. He also emphasized the toxicity profile of TROP2-directed ADCs, particularly gastrointestinal toxicities and myelosuppression. Dr Gerber also reviewed the phase 2 HERTHENA-Lung01 trial (NCT04619004) evaluating patritumab deruxtecan in patients with EGFR-mutant NSCLC and the phase 2 DESTINY-Lung02 trial (NCT04644237) assessing fam-trastuzumab deruxtecan-nxki (Enhertu) in those with HER2-mutant NSCLC. Dr Gerber reflected on the shared DXd payload of these ADCs, highlighting its implications for toxicity and efficacy, as well as open questions regarding treatment sequencing and resistance mechanisms.

En este episodio, cubrimos las noticias más relevantes que están impactando los mercados financieros, la inteligencia artificial y la industria de la salud: Rebote en los mercados: Tras la venta masiva del lunes, el Nasdaq y el $SPX se recuperan con $NVDA subiendo un 5% en premercado. Analizamos el impacto de DeepSeek-R1 y la expectativa por los reportes de ganancias de $MSFT, $META, $TSLA y $AAPL. Energía e infraestructura en IA: Empresas como $VST, $CEG y $PWR se recuperan tras el sacudón tecnológico de DeepSeek. Exploramos cómo la infraestructura energética está evolucionando para soportar el crecimiento de la IA. $SOUN y su movimiento estratégico: SoundHound AI registra una oferta de valores por $500M, lo que presiona a la baja sus acciones. Discutimos las implicaciones de esta venta en el mercado y su estrategia de financiamiento. Alibaba Cloud compite en IA: $BABA lanza Qwen2.5-VL, un modelo que desafía a GPT-4o de $MSFT y Gemini 2.0 de $GOOG en análisis de texto e imágenes. Examinamos cómo Alibaba está posicionando su tecnología en sectores clave. Revolución en oncología: AstraZeneca ($AZN) y Daiichi Sankyo ($DSKYF) reciben aprobación de la FDA para Enhertu, una terapia innovadora contra el cáncer de mama metastásico. Analizamos su impacto en la industria y su potencial en otros tratamientos. Acompáñanos mientras desglosamos estas historias clave y su impacto en los mercados, la tecnología y la salud. ¡Un episodio lleno de información estratégica para inversionistas y entusiastas del sector!

Following the 2024 San Antonio Breast Cancer Symposium (SABCS), Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD, co-hosted a live X Space with CancerNetwork® and spoke about updated trial findings that may impact the breast cancer treatment paradigm. Tarantino is a clinical research fellow at Dana-Farber Cancer Institute and Harvard Medical School. Lambertini is an associate professor and consultant in medical oncology at the University of Genova – IRCCS Policlinico San Martino Hospital in Genova, Italy. Tarantino and Lambertini highlighted data from various studies that investigators presented at the Symposium, which included results on the use of treatment modalities such as antibody drug conjugates and CDK4/6 inhibitors. Some presentations of interest included the following: ·      Phase 3 DESTINY-Breast06 Trial (NCT04494425) o   Patients with hormone receptor (HR)–positive, HER2-low or HER2-ultralow metastatic breast cancer were assigned to receive fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) or physician's choice of therapy. o   Treatment with T-DXd improved progression-free survival (PFS) among patients with a time to progression on frontline endocrine therapy of less than 6 months (HR, 0.38; 95% CI, 0.25-0.59), 6 to 12 months (HR, 0.69; 95% CI, 0.43-1.12), and more than 12 months (HR, 0.67; 95% CI, 0.51-0.88). o   PFS improved with T-DXd regardless of disease burden. ·      Phase 3 EMBER-3 Trial (NCT04975308) o   Investigators evaluated 3 treatment arms—imlunestrant (LY3484356) monotherapy, fulvestrant (Faslodex) or exemestane (Aromasin), and imlunestrant in combination with abemaciclib (Verzenio)—among patients with estrogen receptor (ER)–positive, HER2-negative advanced breast cancer. o   Across the overall population, imlunestrant monotherapy improved PFS compared with standard endocrine therapy (HR, 0.87; 95% CI, 0.72-1.04; P = .12). o   Imlunestrant plus abemaciclib also showed a PFS improvement vs endocrine therapy across the overall population (HR, 0.57; 95% CI, 0.44-0.73; P

In this episode of Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, was joined by Guiseppe Curigliano, MD, PhD, a full professor of medical oncology at the University of Milan, as well as the director of the Early Drug Development Division and co-chair for the Experimental Therapeutics Program at the European Institute of Oncology in Italy.  In this exclusive interview, Drs Park and Curigliano discussed the potential future role of artificial intelligence across oncology disciplines; how advances in precision medicine will help improve patient care; the significance of seeing early research with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) evolve into the present era, where the agent is FDA approved for the treatment of patients with HER2-positive solid tumors. They also discussed their insights on data from the phase 3 DESTINY-Breast06 trial (NCT04494425) investigating T-DXd in patients with HER2-low or -ultralow, hormone receptor–positive, metastatic breast cancer. 

At the 2024 San Antonio Breast Cancer Symposium, Dr. Aditya Bardia, director of the Breast Oncology Program and Translational Research Integration at the UCLA Health Jonsson Comprehensive Cancer Center, presented results from the DESTINY-Breast06 study, showing that Enhertu (chemical name: fam-trastuzumab deruxtecan-nxki), also called T-DXd, was better than chemotherapy for metastatic, hormone receptor-positive, HER2-low or -ultralow breast cancer that grew after one or more hormonal therapy medicines. Listen to the episode to hear Dr. Bardia explain: results of the study what HER2-low and -ultralow breast cancer is whether people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer should have additional HER2 testing

In today's episode, supported by Daiichi Sankyo, we had the pleasure of speaking with Misako Nagasaka, MD, PhD, about the use of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in patients with non–small cell lung cancer (NSCLC). Dr Nagasaka is an associate professor in the Division of Hematology and Oncology and the Division of Medicine at the University of California Irvine School of Medicine.  In our exclusive interview, Dr Nagasaka discussed key findings from the phase 2 DESTINY-PanTumor02 (NCT04482309) and DESTINY-Lung01 (NCT03505710) trials that led to the FDA approval of T-DXd for patients with unresectable or metastatic HER2-positive solid tumors, including those with NSCLC; where next-generation sequencing fits into her clinical practice; and the current role of T-DXd in lung cancer management.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today's episode, we had the pleasure of speaking with Susana M. Campos, MD, MPH, about the role of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in patients with HER2-positive gynecologic cancers. Dr Campos is the clinical director and the director of Educational Initiatives in the Division of Gynecologic Oncology at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School in Boston, Massachusetts. In our exclusive interview, Dr Campos discussed the clinical implications of findings from the gynecologic cancer cohorts of the phase 2 DESTINY-PanTumor02 trial (NCT04482309).

Why has a drug that can extend life for advanced breast cancer patients not been made available on the NHS? NICE have made the decision that Enhertu, a drug that can give around an extra six months to live on average, is too expensive. BBC Health Correspondent Cath Burns joined Anita Rani alongside Kate Wills, who has stage 4 cancer and has been campaigning for the drug to be made available.The actor Lesley Manville is currently starring alongside Mark Strong in Robert Icke's adaptation of Oedipus. She plays Jocasta, Oedipus' wife. Lesley joined Nuala McGovern to tell us more about the play, what it's like being back on stage for the first time since 2020, and why she thinks women's stories are being featured more.New podcast The Kill List follows a group of journalists who discovered a page on the dark web detailing requests to have people killed, with women most likely to be the ones targeted. The investigation led to a major international police operation over four years and, at the heart of it are the real people whose lives were seemingly at huge risk. Nuala was joined by the programme's producer Caroline Thornham and Jennifer whose former husband posted a 'hit' for her on this website.Blessing scams are targeting Chinese communities in the UK. They're usually carried out by women in groups of three, approaching people asking for help in Cantonese. Tuyet van Huynh's mother was one of these victims. After she was targeted, Tuyet set out to expose this practice on social media and has since heard from other victims. She speaks to Anita about the impact the crime has had on their family.Death is a subject many people still shy away from, but one woman is determined to change that. Funeral director Inez Capps is on a mission to challenge the taboos around death and demystify an industry often shrouded in mystery. Inez talks to Nuala about how, since the age of 19, she's been working with the deceased, and she's using social media to give people a glimpse behind the scenes — from the care a loved one receives, to tours of the hearse and the embalming suite.Elkie Brooks is the renowned British rock, jazz and blues singer. In a career spanning six decades, she was the biggest selling female British artist and still holds the accolade of the most Top 75 albums among female artists. She began singing professionally aged 15, shared a bill with The Beatles and went on to front the group Vinegar Joe with Robert Palmer, before going solo. She's currently on her Long Farewell Tour and joined Anita in the studio to talk about her career and turning 80 next year.Presenter: Anita Rani Producer: Annette Wells Editor: Rebecca Myatt

Why has a drug that can extend life for advanced breast cancer patients not been made available on the NHS? NICE have made the decision that Enhertu, a drug that can give around an extra six months to live on average, is too expensive. BBC Health Correspondent Cath Burns joins Anita Rani alongside Kate Wills, who has stage 4 cancer and has been campaigning for the drug to be made available.Do you have an 'emotional vampire' in your life? It's that person who can make you feel drained with their negativity, who isn't taking your own emotions into account. It can make for tricky relationships – so how do you identify an emotional vampire, and how do you handle that person? Chartered psychologist and author Suzy Reading joins Anita to discuss, alongside journalist and author Radhika Sanghani.Elkie Brooks is the renowned British rock, jazz and blues singer. In a career spanning six decades, she was the biggest selling female British artist and still holds the accolade of the most Top 75 albums among female artists. She began singing professionally aged 15, shared a bill with The Beatles and went on to front the group Vinegar Joe with Robert Palmer, before going solo. She's currently on her Long Farewell Tour and joins Anita in the studio to talk about her career and turning 80 next year. In the latest in our series on special educational needs and disabilities we speak to the comedian Josephine Lacey. Today, we are looking at a very personal issue which will resonate for some mothers of boys with SEND. Josephine joins Anita in the studio. Presenter: Anita Rani Producer: Emma Pearce

Six years ago, Helen Addis (aka The Titty Gritty) found a lump. Despite having no history of cancer in her family - it was an aggressive form of breast cancer. A week after her diagnosis - she had a masectomy, followed by 18 months of active treatment. Being well under the screening age, the only person who would have found Helen's cancer - was Helen. During her treatment, Helen asked her friends and family if they checked their boobs - and when most of them said no - she made it her mission to spread awareness about checking your breasts. So, she launched the Change+Check campaign - it is a simple sticker which goes on shop and gym changing room mirrors reminding people to check themselves for signs of breast cancer. She also almost got the queen with a pair of boobs on a Royal Mail stamp…This Breast Cancer Awareness month - Helen is part of a campign to make a life-extending drug called ENHERTU available in England, Wales and Northen Ireland. Despite petitions, protests, campaigns and even government pressure the secondary breast cancer community is being met with constant rejection. They are now fundrasing to raise the legal fees to take legal proceedings to continue the fight for those who need this drug urgently and for the thousands upon thousands who will need it in months and years to come. You can read more about the campaign - and donate hereFollow Helen on Instagram @thetittygrittyEmail us on shouldideletethatpod@gmail.comFollow us on Instagram:@shouldideletethat@em_clarkson@alexlight_ldnShould I Delete That? is produced by Faye Lawrence Music by Alex Andrew Hosted on Acast. See acast.com/privacy for more information.

On Friday the 13th September, Pharmac opened consultation for funding of the medication, Enhertu, for HER2-positive metastatic breast cancer. This comes following the $604 million funding boost allocated to Pharmac to fund and widen access to various medicines.  Trials have shown that the drug can reduce risks of breast cancer patients death by 27%. Producer Josef spoke to the Chief Executive of Breast Cancer New Zealand, Ah-Leen Rayner, about the drug's funding, and what more can be done for breast cancer patients.

On Friday the 13th September, Pharmac opened consultation for funding of the medication, Enhertu, for HER2-positive metastatic breast cancer. This comes following the $604 million funding boost allocated to Pharmac to fund and widen access to various medicines.  Trials have shown that the drug can reduce risks of breast cancer patients death by 27%. Producer Josef spoke to the Chief Executive of Breast Cancer New Zealand, Ah-Leen Rayner, about the drug's funding, and what more can be done for breast cancer patients.

The TROP2 antibody-drug conjugate race has heated up among three Big Pharma companies: Gilead Sciences, AstraZeneca and Merck.  Fierce Pharma's Angus Liu recently took a deep dive into the three TROP2 front-runners. In a feature article, he examined the strengths and potential challenges facing each candidate, as well as the considerations behind their extensive phase 3 programs and their various development strategies. In this week's episode of “The Top Line,” Fierce executive editor Eric Sagonowsky chats with Liu about his feature story on the three TROP2 front-runners. To learn more about the topics in this episode: 3 Big Pharma companies, 33 phase 3 trials: The race for supremacy in an ADC field ASCO: Gilead looks for silver lining in Trodelvy's failed lung cancer trial. But will the FDA play ball? AstraZeneca-Daiichi's Enhertu follow-up Dato-DXd unable to prove overall survival benefit in phase 3 See omnystudio.com/listener for privacy information.

This week ⁠Sarah⁠ continues to fly solo on the podcast with a deep dive into breast cancer with the largest breast cancer charity in the UK, Breast Cancer Now. Sarah is joined by Sally Kum who is the Associate Director of Nursing, Healthcare, Professional Engagement and Health Information who talks about the incredible work done by the charity around research, funding and support for anyone affected by breast cancer. Sally shares some of the latest findings that show breast cancer diagnoses are increasing in the UK and she explains some of the different types of breast cancer. This episode was recorded on 29th July which by chance was the same day on which the the National Institute of Clinical Excellence (NICE) announced the NHS would not be making the drug Enhertu available to patients in England. Enhertu is a life-extending drug for certain women with incurable HER2-low secondary breast cancer, and in an emotional moment, Sarah explores the impact of this and how you can have your voice heard through an online petition. You can read the Enhertu announcement from NICE here. We'd like to hear about your experiences with cancer, so please do get in touch if you'd like to share. If you're listening on Spotify, you can use the show's Q&A feature, or please share your thoughts through our Instagram page at ⁠@howlonghaveyougot2024⁠. And please do like and recommend the show as it helps us reach more members of the cancer community. Studio and recording by ⁠A Digital⁠. Production for A Digital by ⁠Andrew Armitage⁠.

This is the second of the three-part podcast series, Keeping up with the Chemos on Trastuzumab Deruxtecan ENHERTU®.  Our multidisciplinary panel will discuss the important information about the drug preparation and administration of Trastuzumab Deruxtecan ENHERTU®.  Focusing on dosing, breast scoring, HER2, infusion reactions, lab examinations, and patient education. The session ends with general take home points on administration and toxicity prevention interventions.2023-2024 SGO Chemotherapy and Targeted Therapies Subcommittee Member and Moderator:Tracilyn Hall, MDSpeakers:Jennifer MacDonald, PharmD, BCOPKathleen Moore, MDBernard Tawfik, MD 

This is the last of the three-part podcast series, Keeping up with the Chemos on Trastuzumab Deruxtecan ENHERTU®. Our multidisciplinary panel will discuss the challenges with patient monitoring while on Trastuzumab Deruxtecan ENHERTU®. When to dose adjust and hold or even discontinue Trastuzumab Deruxtecan ENHERTU®. Once again, the podcast ends with take home points for patient monitoring and side effects while on Trastuzumab Deruxtecan ENHERTU®.  2023-2024 SGO Chemotherapy and Targeted Therapies Subcommittee Member and Moderator:Tracilyn Hall, MDSpeakers:Jennifer MacDonald, PharmD, BCOPKathleen Moore, MDBernard Tawfik, MD 

This is the first of the three-part podcast series, Keeping up with the Chemos on Trastuzumab Deruxtecan ENHERTU®. After going over some general information on Trastuzumab Deruxtecan ENHERTU® including when to use the drug, checking patient performance status, toxicity, response rates in breast, and line of therapy and treatment option. The multidisciplinary panel will discuss dosing and drug preparation for giving Trastuzumab Deruxtecan ENHERTU®. The session wraps up with some key take home points on Trastuzumab Deruxtecan ENHERTU®.  2023-2024 SGO Chemotherapy and Targeted Therapies Subcommittee Member and Moderator:Tracilyn Hall, MDSpeakers:Jennifer MacDonald, PharmD, BCOPKathleen Moore, MDBernard Tawfik, MD 

Following the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Neil M. Iyengar, MD, and Paolo Tarantino, MD, co-hosted a live X Space with CancerNetwork® and discussed the latest trial updates that may impact clinical practice in the breast cancer field. Iyengar is an associate attending physician at Memorial Sloan Kettering Cancer Center and a co-editor-in-chief of ONCOLOGY®. Tarantino is a clinical research fellow at Dana-Farber Cancer Institute and Harvard Medical School.  Iyengar and Tarantino discussed data regarding several trials and studies presented at the meeting. These presentations included:  ·      Phase 3 DESTINY-Breast06 Trial (NCT04494425)1 o   Investigators evaluated treatment with trastuzumab deruxtecan (T-DXd; Enhertu) compared with investigator's choice of chemotherapy among patients with hormone receptor (HR)–positive, HER2-low or HER2-ultralow metastatic breast cancer. o   The median progression-free survival (PFS) was 13.2 months with T-DXd compared with 8.1 months in patients who received chemotherapy across the HER2-low population (HR, 0.62; 95% CI, 0.51-0.74; P

Conference season kicked into high gear this week with the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and the BIO International Convention in San Diego. Check out BioSpace's ASCO24 Tracker with all the biggest data and other news from the cancer meeting, which wrapped up on Tuesday. Among the trial results highlighted at ASCO24 were BMS' Phase III study results in liver cancer. There was also a lot of news on non-small cell lung cancer (NSCLC): Pfizer presented results from a Phase III trial evaluating its ALK inhibitor Lorbrena, BMS provided three updates on its immunotherapy Opdivo and Opdivo-based combinations, while Gilead unveiled additional details on a failed Phase III trial for its antibody-drug conjugate (ADC) Trodelvy. Currently, there is one ADC approved to treat NSCLC, AstraZeneca and Daiichi Sankyo's Enhertu, for patients with HER2-mutated metastatic disease. While the companies' investigational ADC Dato-DXd is making some headway against NSCLC, experts recently told BioSpace that more compelling surface targets for lung cancer are needed in order for ADCs to really make a difference. When it comes to M&A, Big Pharma continues to show strong interest in oncology, particularly ADCs and radiopharmaceuticals. However, last week's biggest deal was Merck's $3 billion acquisition of EyeBio and its first-in-class trispecific antibody Restoret, marking the company's return to the ophthalmology space after nearly a decade. For now, it appears Big Pharma favors smaller M&A over megabillion-dollar deals. Recent buying activity also indicates a potential resurgence in the appetites of larger companies for psychiatric drug development.

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting featured five days of presentations and educational sessions on all types of cancer. Dr. Eleonora Teplinsky, a board-certified medical oncologist at the Valley-Mount Sinai Comprehensive Cancer Center in Paramus, NJ, summarizes the top breast cancer research. Listen to the episode to hear Dr. Teplinsky explain: the DESTINY- Breast06 study on Enhertu compared to chemotherapy for metastatic hormone-receptor-positive breast cancer how circulating tumor DNA may help predict recurrence descalating treatment to reduce the risk of side effects

Wat doe je als je ziek bent en er in het buitenland een behandeling beschikbaar is die jouw leven kan redden? In BNR Beter twee patiënten die dit overkwam. Waar liepen deze twee ondernemende patiënten tegenaan?  Dwarslaesie De eerste gast is Katelijne Langezaal. Zij brak haar rug in 2016 tijdens een zeiltocht. Het resulteerde in een dwarslaesie: vanaf haar navel tot aan haar tenen was ze verlamd. De reguliere dwarslaesiebehandeling in Nederland gaat langs het revalidatiecentrum waar je leert om te gaan met je beperking: hoe kom je van je rolstoel naar je bed en terug?  Activity Based Therapy Maar in Amerika bleek er een behandeling te zijn die probeert om weer gevoel en functie terug te krijgen onder de dwarslaesie. Dit is Activity Based Therapy. Katelijne zette alles op alles om die behandeling voor zichzelf te organiseren. Dat lukte, met hulp van haar zorgverzekeraar en vrienden en familie. Neuromove En ze ging nog een stap verder: ze richtte een stichting op die deze behandeling in Nederland ging aanbieden, genaamd Neuromove. In de reportage horen we een van de cliënten van Neurmove, Menno Streefland die 20 uur in de week traint om weer zelfstandig te kunnen lopen.  Kanker De tweede gast is Lotte ten Dam. Zij heeft uitgezaaide borstkanker. Om de groei van de kanker te onderdrukken heeft chemotherapie nodig. Tot nu toe werkt de huidige therapie, maar op een gegeven moment gaat de kanker hier doorheen breken. In medische tijdschriften (die Lotte kan lezen omdat ze verpleegkundig specialist is) ontdekte ze een goedgekeurd kankermedicijn dat haar naar verwachting 28 stabiele maanden kan geven. 28 maanden zonder uitzaaiingen en dus een enorm uitstelt tot die onherroepelijke dood. Sluis Een probleem: het medicijn, Enhertu, stond 'in de sluis'. Het medicijn was heel duur, en de overheid moest over de prijs onderhandelen met de farmaceut. Maar het zat al een hele tijd in die sluis. En Lotte's tijd begon te tikken. Tijd voor actie dus! Influencer? 'Je moet zorgen dat je viraal gaat', zei een vriendin tegen Lotte. 'Word ik echt zo iemand?', vroeg Lotte zich af. Maar als je leven in de waagschaal ligt, stap je toch net iets makkelijker over je gêne heen. Ze ging brieven schrijven aan de ministers, Kamerleden en zocht de pers op.  Toevallig of niet, kwam het medicijn niet lang daarna uit de sluis. En nu ligt het op de plank voor Lotte en vele andere mensen met allerlei vormen van kanker.     Presentator: Nina van den Dungen Redactie en reportage: Sterre ten Houte de LangeSee omnystudio.com/listener for privacy information.

Listen to a soundcast of the April 5, 2024, FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-positive solid tumors.

In their recent earnings call, AstraZeneca, led by CEO Pascal Soriot, shared their financial performance and future strategies with investors. The dialogue underscored both the company's recent progress and its forward-looking plans within the context of the global healthcare sector.AstraZeneca reported notable financial performance, with a 19% increase in overall revenue and a 13% rise in core earnings per share. Their growth has been further bolstered by an 18% increase in product sales, indicating a wholesome financial status. AstraZeneca points to key products, such as Tagrisso, Lynparza, Imfinzi, Calquence, Enhertu, and Ultomiris, as significant contributors to the company's expansion. Furthermore, new additions like Tagrisso combined with chemotherapy and the HER2 tumor-agnostic solution have supplemented the company's product assortment.Consumer trends, as presented by AstraZeneca during their earnings call, depict a robust demand for their pharmaceuticals across various therapeutic areas, including oncology, biopharma, and rare diseases. The company's growth, driven by such widespread demand, suggests a solid market position, based on the evidence from the earnings call.Furthermore, AstraZeneca has demonstrated a commitment to strategic investments, as can be inferred from their involvement in Fusion Pharmaceuticals and Amolyt Pharma. The company's emphasis on diversification and capability enhancement appears to be a primary goal. In the same vein, AstraZeneca's focus on spearheading eight pivotal trials and exploring emerging fields like cell and gene therapies positions them as a potential leader in oncology and beyond.Soriot, during the earnings call, provided insights into the company's perspective, stating, "And we'll keep that in mind as we continue to design our clinical development program." It indicates AstraZeneca's ongoing commitment to optimizing their clinical development strategy to address evolving healthcare requirements. However, while AstraZeneca has demonstrated success in recent periods, it is essential to remember that the path forward – full of challenges and opportunities – in the extremely competitive and complex healthcare sector is by no means certain and the decisions and strategies announced during this call constitute only the company´s current view and could be subject to changes. AstraZeneca's future performance should be observed in this context of uncertainty inherent to the pharmaceutical industry. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.theprompt.email

·       Nascentmc.com for medical writing assistance for your company.Visit nascentmc.com/podcast for full show notes Cilta-cel for Myeloma: The FDA approved ciltacabtagene autoleucel (Carvykti; cilta-cel) for adults with relapsed or refractory multiple myeloma who have tried at least one prior therapy including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. This CAR T-cell therapy, initially approved in 2022, was confirmed effective in the phase 3 CARTITUDE-4 study, showing significant reduction in disease progression or death risk by 59% compared to standard care. Enhertu for HER2-positive Solid Tumors: Fam-trastuzumab deruxtecan-nxki (Enhertu) received FDA approval for treating unresectable or metastatic HER2-positive solid tumors in adults who have had previous systemic treatment and lack satisfactory alternative options. This therapy, a conjugate of an anti-HER2 antibody and a cytotoxic drug, was first approved in 2019 and targets HER2-expressing cancer cells to potentially minimize damage to normal tissues. Fanapt for Bipolar: Iloperidone (Fanapt) has been approved for the acute treatment of manic or mixed episodes in adults with bipolar I disorder. Previously approved for schizophrenia, iloperidone targets neurotransmitters like dopamine and serotonin. It demonstrated efficacy in a pivotal trial, showing significant improvement on the Young Mania Rating Scale. Zevtera for Multiple Bacterial Infections: Ceftobiprole medocaril sodium (Zevtera) was approved for treating adults with Staphylococcus aureus bloodstream infections, right-sided infective endocarditis, and acute bacterial skin and skin structure infections. Also approved for pediatric community-acquired bacterial pneumonia, ceftobiprole is a broad-spectrum cephalosporin that combats various bacteria including MRSA. TriClip for Tricuspid Regurgitation: The FDA approved the TriClip™ transcatheter edge-to-edge repair system for treating tricuspid regurgitation. This minimally invasive option clips the tricuspid valve leaflets to improve blood flow and prevent the need for surgery. The TRILUMINATE Pivotal trial showed significant improvements in TR severity and quality of life with a good safety profile. Revumenib for Acute Leukemia: The FDA granted priority review to revumenib (SNDX-5613) for treating adult and pediatric patients with relapsed or refractory acute leukemia with KMT2A rearrangements. As a new therapeutic agent, revumenib inhibits the menin-MLL protein interaction crucial in leukemic transformation. Early trial results show promising remission rates, with a PDUFA action date scheduled for September 26, 2024.  

In this episode, Laura talks to Hannah Gardner about the life-extending drug Enhertu, which has just been rejected for use on the NHS in England. This means thousands of women, including Hannah, will be denied access to a drug that could've given them the hope of more time to live. Join Hannah and Breast Cancer Now in calling on NICE, NHS England and the drug companies Daiichi Sankyo and AstraZeneca, to do everything possible to make Enhertu available on the NHS. Hannah also shares how life with secondary breast cancer is for her and her 3-year-old daughter. She discusses her previous career as a clinical trials manager, and what it was like to be on the other side of the table when she joined a clinical trial herself. Hannah also describes the devastating impact of finding out she may be denied the drugs that could give her more time. You can follow Hannah on Instagram @realhouseofhannah We're Breast Cancer Now, the research and support charity. However you're experiencing breast cancer, we're here. For information and support, visit our website or phone our free helpline on 0808 800 6000 (UK only). You can also watch this episode on YouTube. Key Topics: 0:00 Introduction 0:24 Laura introduces Hannah 1:00 How Hannah was first diagnosed with breast cancer 3:35 Hannah's treatment 4:01 Difficulty getting the diagnosis 6:08 Hannah talks about being diagnosed with secondary breast cancer 10:36 The effect of the diagnosis on Hannah's daughter 15:33 Treatment for secondary breast cancer 16:07 Hannah's experience with clinical trials 25:01 How breast cancer affected Hannah's body image 29:59 Looking well with an invisible illness 31:40 Enhertu and HER2-low breast cancer 37:31 Breast Cancer Now's Enhertu open letter campaign 39:30 An update on Enhertu and what it means for Hannah 50:38 What you can do to help Breast Cancer Now make a difference 54:01 Differences in how primary and secondary patients are treated 57:46 What needs to change in breast cancer?

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-adc-therapies-for-nsclc-anticipating-aes-reported-in-clinical-trials/18170/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/adc-related-hematologic-adverse-events/18169/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/optimal-management-of-adc-related-gastrointestinal-aes-in-nsclc/18168/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-adc-related-pulmonary-and-cardiac-aes-in-nsclc/18167/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/adcs-in-gynecologic-cancers-managing-pulmonary-and-cardiac-teaes/18171/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/hematologic-adverse-events-with-adcs-in-breast-cancer-optimal-management-strategies/18165/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/risk-reduction-and-management-protocols-for-gastrointestinal-adverse-events-with-adc-therapy-in-breast-cancer/18164/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-pulmonary-and-cardiac-adverse-events-related-to-adc-therapy-in-breast-cancer/18163/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/gastrointestinal-and-hematologic-teaes-related-to-adc-therapy-in-gynecologic-cancers/18172/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

CME credits: 1.00 Valid until: 19-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/adcs-on-the-horizon-for-breast-cancer-managing-treatment-emergent-toxicities/18166/ "Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

“Enhertu se proyecta como la opción terapéutica más importante para pacientes oncológicos en los próximos años y ha demostrado mejora tanto en supervivencia sin progresión como en supervivencia general”.Hoy a las 5 de  la tarde por los 107.3 FM de Omega Stereo.LIVE por las cuentas de Facebook Omega Stereo y Grupo Pauta Panamá.También por omegastereo.com#cancerdemama#oncologia

Last week, we saw some research regarding how a popular tool used to plan breast cancer treatment may be misguiding therapy for Black women, as well as an update on when we can expect to see a new cancer vaccine be readily available for patients.  And on the FDA front, we'll discuss a priority review for Enhertu for patients with HER2-positive solid cancers, as well as a fast track designation for a new drug duo in the lung cancer space.  Cancer Vaccine Likely ‘Several Years' Away From Wide Availability ELI-002 is a vaccine being investigated for the treatment of patients with KRAS-mutant pancreatic or colorectal cancers. While cancer vaccines have been in the headlines a lot in recent months, this one, at least, is still a ways away from being readily available for patients across the United States.  Findings from a phase 1 trial showed that the vaccine could be beneficial for this patient population, and now, a phase 2 trial recently started that will evaluate the efficacy of an injection version of ELI-002, compared to observation. The first patient was dosed in the trial in January 2024, so it could still be several more years until the drug is available, Dr. Christopher Haqq, chief medical officer and vice president, head of research and development at Elicio Therapeutics, said in an interview with CURE®.  “We'll be talking to the regulators like the US Food and Drug Administration and others around the world to align on the data that we'll need to provide for a marketing application. And so, we haven't had that input yet. So I can't give an exact answer for you (on when the vaccine will be commercially available). But we'll work as fast as possible. It's even possible that the type of evidence that we gather in this randomized study could serve that purpose. But we won't know until we have further discussion,” he said.  Test May Be ‘Misguiding' Breast Cancer Treatment for Black Women  A recent study showed that the 21-gene breast recurrence score may lead clinicians away from prescribing chemotherapy to Black women who may benefit from the treatment.  The 21-gene breast recurrence score is the standard test to help guide treatment decisions for patients with estrogen receptor-positive (also known as ER-positive) disease. Most patients with ER-positive cancer undergo hormone therapy, but the outcomes for this test may help decide if a patient would benefit from additional chemotherapy, too. Now, findings from a recent study discovered that Black women — and younger Black women, in particular — may be missing out on chemotherapy that they could potentially benefit from.  Now, this research team is conducting further research looking at potential molecular differences in breast cancer in Black women, as well as how other social disparities could be playing into an increased risk of breast cancer death in these women.  FDA Grants Priority Review to Enhertu for HER2-Positive Solid Cancers  The Food and Drug Administration granted a priority review for a supplemental biologics license to Enhertu for the treatment of patients with previously treated metastatic HER2-positive solid tumors that cannot be removed via surgery. Basically what that means is that the drug showed promise in a clinical trial, and now the FDA will work with the pharmaceutical company developing the drug to expedite the review and potential approval of the agent. The agency plans on making its decision on whether or not Enertu will be approved some time in the second quarter of this year.  Enertu is an antibody drug conjugate, which is a type of drug that works by finding and binding to certain proteins found on cancer cells — in this case, the HER2 protein. The drug was previously approved for patients with lung cancer and metastatic breast cancer, and now, the phase 2 DESTINY-PanTumo02 trial will help determine if it will be approved for patients with endometrial, cervical, ovarian, bladder, biliary tract, pancreatic or other cancers that are HER2 positive.  FDA Grants Fast Track Designation to Avutometinib-Lumakras Combo Also in the regulatory space, the FDA granted a fast track designation to a two drug combination consisting of Lumakras and the novel agent, avutometinib for patients with KRAS G12C-mutant metastatic non-small cell lung cancer. The intended patient population for the regimen is those who have been treated with at least one systemic therapy and have not received a KRAS G12C inhibitor.  The regimen is being investigated in the ongoing phase 1/2 RAMP 203 trial, which will analyze the effectiveness of the drug, as well as the overall response rate — which is the percentage of patients whose cancer decreases from the drug — and safety. Findings from the second phase of the trial, which is specifically looking at patients who have not received or did not respond to a KRAS G12-inhibitor are expected to be published some time in the first half of 2024.   For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. Today, we have several news updates from the industry. Let's dive in.Cigna has sold its Medicare businesses to HCSC for $3.7 billion, exiting a sector that has seen its earnings potential shrink. Despite the sale, Cigna still sees Medicare Advantage as an area for future growth. In other news, the No Surprises Act prevented 10 million surprise bills in the first nine months of 2023, according to insurer groups AHIP and BCBSA. However, they also criticized providers for allegedly abusing the billing dispute resolution process set up by the law. Tenet Healthcare plans to sell four California hospitals to UCI Health for $975 million as part of its efforts to reduce debt. An AI-powered solution is being touted as a way to alleviate the critical shortage of medical coders and boost efficiency and revenue in healthcare systems.In the biotech world, Arch is raising $3 billion for startup investing, continuing its track record of creating and investing in biotech startups. Vertex's non-opioid drug showed positive results in a major trial for pain relief, although it fell short compared to a widely prescribed opioid on a secondary goal. Cell therapy for lupus is gaining attention, with several drugmakers conducting trials in this area. Biogen has decided to discontinue its controversial drug Aduhelm and return the rights to the original developer. AstraZeneca and Daiichi are seeking FDA approval for their drug Enhertu as a "tumor agnostic" treatment. Roche has made changes to its early-stage pipeline, focusing on experimental programs for obesity.In recent developments, Philips has stopped selling sleep and respiratory devices in the US due to a consent decree from the FDA. Teleflora used a documentary approach in its marketing campaign to overcome cynicism about love, while Lay's released time-loop ads inspired by the movie "Groundhog Day." Ocean Spray revealed its first major brand overhaul in over 20 years, and Miller Lite turned fans into walking beer ads for the Super Bowl. McDonald's also made headlines with its Hamburglar character hitting the road in a getaway vehicle. Pepsi Wild Cherry created excitement around the Super Bowl with a Vegas sphere takeover.Cigna is still interested in the Medicare Advantage market despite selling its Medicare division. Providence plans to settle allegations of not fulfilling charity care obligations. Walgreens has confirmed additional layoffs as part of its ongoing efforts to achieve cost savings. The Department of Health and Human Services has finalized a rule on telehealth at opioid treatment programs. A new study found that the availability of telehealth for mental healthcare varies by state. Healthcare executives must consider workforce and consumer concerns about generative AI, according to a survey.Alto Neuroscience and Fractyl Health have both gone public in separate IPOs, joining the recent surge of biotech IPOs. The CMS has sent initial price proposals to drugmakers as part of efforts to reform drug pricing. Kyverna Therapeutics is planning an IPO to support the development of its anti-CD19 CAR-T therapies. The Department of Health and Human Services released new data showing that Americans pay significantly more for prescription drugs compared to other developed countries. The ASGCT Annual Meeting will cover topics such as genome editing, muscular dystrophy, and cell and gene therapy.In financial news, AbbVie reported a beat in its Q4 earnings but expects sales decline in oncology and immunology. Bristol Myers Squibb exceeded Q4 estimates and is looking towards new products and M&A following exclusivity loss. Merck posted $60 billion in sales for 2023 driven by Keytruda and HPV vaccine. GlaxoSmithKline saw an increase in sales thanks to vaccines for RSV and shingles. Takeda reported lower profits but closed a $300 million deal with Protagonis

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. AstraZeneca, the pharmaceutical company, recently had its day in court regarding a potential injunction on the Medicare drug pricing law. The outcome of the hearing will have significant implications for the healthcare industry. Meanwhile, Vertex Pharmaceuticals' non-opioid pain drug failed to outperform Vicodin in clinical trials, but experts believe that more can be done to develop effective non-opioid pain medications. In other news, a study has found that the Inflation Reduction Act's drug price negotiation program will have only a modest impact on global biopharma revenues and is unlikely to result in significant cuts to research and development. Sanofi reported a $600 million net loss in Q4 2023 due to various factors, despite strong sales of its blockbuster drug Dupixent. Additionally, Roche's 2024 strategy aims to combat low growth through pipeline cuts and mergers and acquisitions. Daiichi Sankyo has raised its sales forecast for Enhertu due to non-US growth, and the FDA Commissioner has highlighted adcomm reform, funding, and AI as priorities for the agency.Moving on to other industries, Pepsi is generating excitement for the Super Bowl with its "Get Wild" campaign for Pepsi Wild Cherry. Gatorade, another brand under PepsiCo, is launching a free membership platform to fuel its digital transformation. Jif, the peanut butter brand, is tackling "celery neglect" on game day by offering free peanut butter through a tie-up with Gopuff. In social media news, CEOs faced tough questions about child protection in a Senate session, with senators arguing that social platforms need to do more to protect young users. Advertiser Perceptions' Erin Firneno advises media companies on how to communicate brand momentum in 2024. The Super Bowl LVIII ads are being tracked, with reveals from Michelob Ultra and Paramount+, and teasers from Uber and Nyx. Google, CrowdStrike, and State Farm will also be returning with ads. Lastly, Marketing Dive's daily newsletter offers insights and news for marketing leaders.In the field of research, BioIVT is a leading provider of control matrices, offering biofluids, tissues, and matrices from commercial animals for research purposes. These biospecimens undergo strict quality control measures to enhance assay sensitivity. BioIVT offers a wide range of control matrices, including serum, cerebrospinal fluid (CSF), ocular fluid, and various tissues. These samples can be shipped fresh, cold, or frozen to ensure reliability and quality. Additionally, BioIVT provides matrices from commercial animals.Thank you for listening to Pharma and Biotech daily. Stay tuned for more important updates in the world of Pharma and Biotech.

In this episode, we delve into the exciting developments in antibody drug conjugates (ADCs) presented at the 2023 San Antonio Breast Cancer Symposium.ADCs are a promising class of treatment that combines an antibody with a chemotherapy drug, aiming to target and kill cancer cells more effectively while reducing side effects. We discuss approved ADCs like Enhertu and Trodelvy, and highlight that there's an ADC available for every breast cancer subtype. With many more ADCs in clinical and preclinical trials, the future looks hopeful for breast cancer treatment.We explain the structure of ADCs, which includes the antibody that targets cancer cells, the cytotoxic drug that kills the cells, and the linker that holds them together. We also touch on the importance of choosing treatment types based on personal circumstances, such as age and family responsibilities, as different treatments come with varying side effects.During the episode, we cover two clinical trials in detail. The first is about Datopotamab Deruxtecan (DATO-DXD), which showed promising results in hormone receptor-positive, HER2-negative patients, offering increased progression-free survival and different side effect profiles compared to traditional chemotherapy. The second trial combined DATO-DXD with the immunotherapy drug Durvalumab for advanced and metastatic triple-negative breast cancer, showing a high response rate and manageable side effects.Our guest, Katie, shares her personal experiences with ADCs and provides insights into side effect management. She emphasizes the importance of dose adjustments and monitoring for specific side effects like nausea, vomiting, and interstitial lung disease. Katie also mentions the ongoing research to optimize dosing, detect side effects earlier, and engineer drugs with lower toxicity.As always, we remind our listeners that the information shared on our podcast is based on personal experiences and is not a substitute for professional medical advice. We encourage you to reach out to your medical care team with any questions or concerns.00:00:47 - Overview of Antibody Drug Conjugates (ADCs)00:03:37 - FDA-Approved ADC Examples00:04:49 - Datopotamab Deruxtecan (DATO-DXD) Clinical Trial Insights00:07:10 - Combining DATO-DXD with Immunotherapy00:08:23 - Managing ADC Side Effects00:09:53 - Specific Recommendations for Current ADCs00:11:09 - Future Directions in ADC Development+++++++++++++++++++++Attend a free virtual SurvivingBreastCancer.org event:https://www.survivingbreastcancer.org/eventsFollow us on InstagramLaura and Will: https://www.instagram.com/laura_and_will/SurvivingBreastCancer.org: https://www.survivingbreastcancer.org/Breast Cancer Conversations: https://www.instagram.com/breastcancerconversations/About SurvivingBreastCancer.org: SurvivingBreastCancer.org, Inc. (SBC) is a federally recognized 501(c)(3) non-profit virtual platform headquartered in Boston with a national and global reach. Through education, community, and resources, SurvivingBreastCancer.org supports women and men going through breast cancer. We provide a sanctuary of strength, compassion, and empowerment, where those diagnosed with cancer unite to share their stories, learn invaluable coping strategies to manage wellness and mental health, and find solace in the unbreakable bond that fuels hope, resilience, and the courage to conquer adversity.Support the show

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. Sarepta Therapeutics has released data on its new drug for Duchenne muscular dystrophy, showing potent boosting of dystrophin protein production. However, some side effects, including electrolyte imbalances, were also highlighted. Astrazeneca and Daiichi are seeking FDA approval for their drug Enhertu as a "tumor agnostic" treatment, and the FDA is currently reviewing their application. Bristol Myers has received positive data from a trial of a subcutaneous formulation of Opdivo in kidney cancer, showing similar efficacy to the intravenous formulation. Biotech IPOs continue to be an important source of funding for the industry, with Alto Neuroscience and Fractyl Health preparing for initial stock offerings. Merck Manuals is focusing on a "one health" approach, integrating human, animal, and environmental health in medical education and practice.Philips has announced that it will stop selling sleep and respiratory devices in the US due to a consent decree from the FDA. This decision comes as Philips faces regulatory scrutiny and potential legal action related to quality issues with its sleep apnea devices. Medical device companies Stryker, Boston Scientific, and BD are set to post their earnings this week. Absolutions has received FDA breakthrough designation for its abdominal wall closure device, aiming to reduce the risk of hernia by distributing suture tension over a large area of tissue. Globus has laid off employees from NuVasive following their merger. Masimo has forced Apple to redesign its smartwatches in a long-running patent dispute.The pharmaceutical industry is in a race to develop groundbreaking drugs for pain relief. Tanezumab, developed by Eli Lilly and Pfizer, was dropped due to safety concerns. Attention has turned to Vertex Pharmaceuticals' candidate vx-548, which has shown positive results in phase 2 trials for chronic nerve pain. South Rampart Pharma has won fast track designation for its novel drug that activates pain signaling pathways without causing liver and kidney toxicities. Tonix Pharmaceuticals is repurposing an existing technology for the treatment of fibromyalgia, with positive late-stage results. These developments offer hope for patients suffering from chronic pain conditions and could generate significant revenue for the companies involved.Overall, these developments highlight ongoing challenges and changes in the medtech industry, including regulatory scrutiny, mergers, and patent disputes. Medtech companies must navigate these complexities while leveraging connected ecosystems, data, and strategic planning to drive innovation in healthcare.Thank you for tuning in to Pharma and Biotech daily. Stay informed, stay ahead.

In a conversation with CancerNetwork®, Sarah Donahue, MPH, NP, discussed strategies for managing adverse effects (AEs) associated with different drug classes for patients with metastatic breast cancer, ranging from antibody drug conjugates (ADCs) to CDK4/6 inhibitors. With respect to ADCs, Donahue, a nurse practitioner at University of California, San Francisco, and member of the Oncology Nursing Society, highlighted common AEs following treatment with trastuzumab deruxtecan (T-DXd; Enhertu) and sacituzumab govitecan-hziy (Trodelvy). In particular, she spoke about the necessity of managing nausea associated with T-DXd by helping patients schedule doses with antiemetic drugs, as well as mitigating fatigue and improving quality of life in the process. For those who are treated with sacituzumab govitecan, Donahue spoke about mitigating abdominal cramping at her infusion center and administering loperamide to help patients manage acute diarrhea. Donahue also discussed her methods for managing toxicity related to CDK4/6 inhibitors including palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenios). Among patients with hormone receptor (HR)–positive breast cancer, treatment with palbociclib and ribociclib, when given in combination with hormonal therapy, may result in fatigue, hot flashes, and arthralgia. According to Donahue, encouraging patients to exercise often may combat fatigue while mitigating arthralgia associated with an aromatase inhibitor. Moreover, she stated that loperamide may help manage potential diarrhea following treatment with abemaciclib.  Overall, Donahue underscored the importance of keeping patients on treatments with CDK4/6 inhibitors and other treatments by being communicative with them regarding the potential to alleviate AEs. She suggested that such openness may give patients the confidence to ask providers for guidance on how to manage their disease.   “The main thing that I find most helpful for my patients is to explain the potential [adverse] effects, explain that there's something that we can do about them—that we can intervene. If they reach out to us sooner, we can help them more,” Donahue concluded. “I hope that the providers who are listening to this now can help to empower their patients to reach out and to ask for advice. That's the best thing that they can do to keep them on these medications longer. They can work well; we can show that in studies. But if we can't keep [patients] on the medications, then what are we doing?”

In a recent conversation with CancerNetwork®, Sara A. Hurvitz, MD, FACP, senior vice president and director of the Clinical Research Division at Fred Hutch Cancer Center and head of the Division of Hematology and Oncology at the University of Washington Department of Medicine, discussed new treatment options for patients with metastatic HER2-positive breast cancer.  In the discussion, Hurvitz highlighted findings from the phase 3 HER2CLIMB-02 trial (NCT03975647), which assessed the efficacy and safety of tucatinib (Tukysa) plus ado-trastuzumab emtansine (Kadcyla; T-DM1) in patients with HER2-positive breast cancer, specifically those with brain metastases.  Patients enrolled in this trial experienced a significant improvement in progression-free survival (PFS) with the tucatinib-based regimen. Data presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) highlighted that the median time to disease progression or death was 9.5 months (95% CI, 7.4-10.9) and 7.4 months (95% CI, 5.6-8.1 in the experimental arm and placebo arm, respectively (HR, 0.76; 95% CI, 0.61-0.95; P = .0163). In patients with brain metastases, the median time to disease progression or death was 7.8 months (95% CI, 6.7-10.0) and 5.7 months (95% CI, 4.6-7.5) in the experimental arm and placebo arm, respectively (HR, 0.64; 95% CI, 0.46-0.89). Investigators reported that toxicity in the experimental arm was generally manageable and reversible. “This was a study that only enrolled patients who were naive to trastuzumab deruxtecan [T-DXd; Enhertu],” Huvitz said. “We know that T-DXd has substantial improvements in PFS and survival, so having so many patients receive this [agent] after progression is certainly going to impact our ability to observe survival differences. About 15% of patients in each arm also went on to receive tucatinib. These are pretty exciting results for our patients, especially those with brain metastases. This study did enroll, as I said, patients with brain metastases, who comprised 44% or so of the entire population enrolled in this study. These are interesting data, and we'll see if this regimen is ultimately approved.” Reference Hurvitz SA, Loi S, O'Shaughnessy J, et al. HER2CLIMB-02: randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer. Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023; San Antonio, TX. Session GS01-10.

In a recent discussion with CancerNetwork®, Joleen Hubbard, MD, research collaborator with Mayo Clinic and deputy director for clinical research at Allina Health Cancer Institute in Minneapolis, Minnesota, discussed new opportunities for patients with colorectal cancer (CRC).   In the discussion, Hubbard highlighted the potential of trastuzumab deruxtecan-nxki (Enhertu; T-DXd) in patients with HER2-expressing metastatic CRC based on studies including the phase 2 DESTINY-CRC01 trial (NCT03384940), which assessed the efficacy and safety of the agent in those who progressed after 2 or more prior regimens.1  These trials may play a role in continuing HER2 inhibition downstream after the FDA approval of trastuzumab (Herceptin) plus tucatinib (Tukysa) in patients with metastatic HER2-positive CRC.2   Hubbard also discussed the phase 3 MOUNTAINEER-03 study (NCT03043313) and its effects in the CRC space.3 This trial assessed the safety and efficacy of frontline tucatinib and trastuzumab in patients with treatment-refractory, RAS wild-type, HER2-positive metastatic CRC. Primary endpoints for this analysis showed a clinically meaningful overall response rate of 38.1% and a median duration of response of 12.4 months. Additionally, the treatment combination was well tolerated.   She said she is “optimistic” that moving HER2-directed therapy to the first-line setting, as seen in the MOUNTAINEER-03 study, may help outcomes for patients with metastatic CRC.  “It's a very exciting space,” Hubbard said. “Because it's only 5% to 8% of patients [who have CRC], it may not get as much attention, but there's 150,000 new cases of [CRC] diagnosed each year. So, 5% to 8% of that is a large number of patients [whom] we need to be looking at, studying, and potentially impact with these treatments.”  References  Yoshino T, Di Bartolomeo M, Raghav K, et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun. 2023;14(1):1-13. doi:10.1038/s41467-023-38032-4   Seagen announces FDA accelerated approval of Tukysa (tucatinib) in combination with trastuzumab for people with previously treated RAS wild-type, HER2-positive metastatic colorectal cancer. News release. FDA. January 19, 2023. Accessed December 6, 2023. https://bwnews.pr/3Xpzbqn  Bekaii-Saab TS, Van Cutsem E, Tabernero J, et al. MOUNTAINEER-03: phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress. J Clin Oncol. Published online January 24, 2023. doi:10.1200/jco.2023.41.4_suppl.tps261 

Ashley Gaines is Vice President, Head of Breast Cancer Franchise, US Oncology Business Unit, at AstraZeneca ( https://www.astrazeneca-us.com/az-in-us/ashley-gaines.html ) where she is responsible for overseeing commercialization in the US for ENHERTU, TRUQAP and future breast cancer assets and indications. Ashley joined AstraZeneca in 2014 and has led commercial teams across various US and Global franchises, including Infectious Disease, Women's Cancers, Lung Cancer and Hematologic Cancers. Her experience prior to AstraZeneca includes marketing and strategy, investment banking and management consulting roles at Pfizer, McKinsey & Co. and Goldman, Sachs & Co. Ashley has a Bachelor of Arts, Math and Urban Studies, from University of Pennsylvania, and a Master of Business Administration, General Management, from Harvard Business School. Support the show

Last week was Veterans' Day, and for some individuals in the armed service, that means reflecting back on their service, as well as the potential cause of their cancer. For both print and web-first features, CURE® spoke with veterans about their cancer journeys, including one Iraq veteran whose cancer was likely caused by exposure during his deployment overseas.  Regarding new drug indications last week, the FDA seemed to be working in the gastrointestinal space: we saw a new drug approved for certain patients with colorectal cancer, and other indication in the gastric cancer space slightly changed from the way it was originally approved a few years ago.  Finally, it is the open enrollment period for people who are eligible for Medicare. We heard from an expert at City of Hope about why patients with cancer should do their research before choosing a plan.  Veteran, Colon Cancer Survivor Explains Importance of PACT Act  Last year, President Joe Biden signed the bipartisan Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics (PACT) Act into law last year, with the White House calling it “the most significant expansion of benefits and services for toxic exposed veterans in more than 30 years.” More than 4.1 million veterans received free toxic exposure screenings through the VA, with the government processing nearly half a million PACT Act claims and delivering more than $1.85 billion in PACT Act-related benefits to veterans and survivors, including $215 million in benefits to veterans with cancer, during the first year of the PACT Act, the White House stated. Under the PACT Act, for example, all gastrointestinal cancers are considered toxic exposure presumptive conditions — meaning veterans do not have to prove that the cancer started during or worsened because of their military service — for veterans from the Gulf War and post-9/11 eras such as Dan Nevins, a U.S. Army Reserve veteran and stage 3 colon cancer survivor who served in Iraq. Read more: Veterans On The Front Lines of Lung Cancer Dan is a bilateral, below-knee amputee living with a traumatic brain injury as a result of his service, and he received his cancer diagnosis in late 2021. Spoke with us about his experiences being exposed to burn pits in Iraq. FDA Approves Fruzaqla for Previously Treated Metastatic Colorectal Cancer Last week came with another Food and Drug Administration approval in the oncology space. Fruzaqla for patients with metastatic colorectal cancer that has been previously treated with certain chemotherapy drugs, anti-VEGF therapies, and — if the patient has RAS wildtype disease and its medically appropriate — an anti-EGFR therapy.  The approval, which was announced on Wednesday night, was based on findings from two clinical trials: FRESCO and FRESCO-2, which both showed that Fruzaqla improved overall survival (time from treatment until death of any cause) compared to placebo in this patient population.  Of note, Fruzaqla is an oral drug that is not a chemotherapy agent, which may help patients avoid an abundance of clinics for treatment, as well as some of the side effects associated with chemotherapy, though we should note that Fruzaqla, like all drugs, does have its own set of potential side effects.  FDA Amends Keytruda Approval for Gastric, GEJ Cancer Also on the FDA front, the agency announced on Thursday that it was revising the approval indication of Keytruda plus Enhertu and chemotherapy for the frontline treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.  The Keytruda-containing regimen was originally approved in May 2021 and was for patients regardless of their cancer's PD-L1 status. PD-L1 is a protein found on the surface of tumor cells and acts as a kind of cloak of invisibility from the immune system. Checkpoint inhibitor drugs like Keytruda inhibit the function of PD-L1, thereby allowing the immune system to find and fight the cancer. With the amended approval, the FDA is now stating that this Keytruda regimen should only be used in patients whose cancers have that PD-L1 protein, as determined by a companion diagnostic test.  This change came after follow-up data from the KEYNOTE-811 trial were presented at the European Society for Medical Oncology Congress a couple of weeks ago. The findings showed that while the Keytruda plus Enhertu and chemotherapy improved outcomes over placebo plus Enhertu and chemotherapy, the benefit was particularly better for those whose disease was PD-L1 positive.  When It Comes to Cancer Care, Not All Medicare Plans Are the Same The Medicare open enrollment period has officially begun and will run until Dec. 7.  In a CURE® exclusive article penned by Dr. Harlan Levine of the City of Hope, a popular type of Medicare — Medicare Advantage — is outlined, along with their potential pros and cons when facing a cancer diagnosis. For example, did you know what while Medicare Advantage tends to be a more affordable option, it may not cover research medical centers that provide patients with cancer access to advanced treatments and clinical trials?  Dr. Levine and others are advocating for Medicare Advantage to cover treatment at comprehensive cancer centers, but until then, he warns individuals to be weary of the plans that they choose and always read the fine print.   For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.

Ritu Salani, MD, and Tanios S. Bekaii-Saab, MD, FACP, spoke with CancerNetwork® about key findings presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, and how they may affect clinical practice for gynecologic cancer and gastrointestinal cancer. Salani, the Gynecologic Oncology Fellowship Director at University of California Los Angeles (UCLA) Health and the Gynecologic Oncology editorial board member for the journal ONCOLOGY®, discussed presentations on the treatment of ovarian cancer and other gynecologic malignancies. These included data on dostarlimab-gxly (Jemperli) in advanced or recurrent endometrial cancer in the phase 3 RUBY trial (NCT03981796), mirvetuximab soravtansine-gynx (Elahere) in folate receptor alpha–high platinum-resistant ovarian cancer in the phase 3 MIRASOL trial (NCT04209855), and a bevacizumab (Avastin)-based regimen in newly diagnosed ovarian cancer in the phase 3 DUO-O trial (NCT03737643). Bekaii-Saab, leader of the Gastrointestinal Cancer Program at the Mayo Clinic Comprehensive Cancer Center; medical director of the Cancer Clinical Research Office; vice chair/section chief for Medical Oncology, Department of Internal Medicine, at Mayo Clinic, Phoenix, Arizona; and the Gastrointestinal Cancer chair for the ONCOLOGY® tumor board, detailed findings from presentations in the gastrointestinal cancer space. He discussed data on fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-positive metastatic colorectal cancer (CRC) in the phase 2 DESTINY-CRC02 study (NCT04744831), sotorasib (Lumakras) in advanced solid tumors with KRAS G12C mutations in the phase 1b/2 CodeBreaK 101 trial (NCT04185883), and bevacizumab plus atezolizumab (Tecentriq) in metastatic CRC in the phase 2 AtezoTRIBE trial (NCT03721653). Don't forget to subscribe to the “Oncology On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

In this episode of our Road To A Cure series, we talk with oncologist and researcher Dr. Erika Hamilton about the practice-changing developments of the past 15 months. This is a timely discussion as research continues to catch up to need in our lives with metastatic breast cancer. 2022 brought the big news that an anti-body drug conjugate, Enhertu, was delivering results in people with what was then known as HER2-negative breast cancer. Suddenly the term HER2-Low was everywhere. Of course, the news in 2022 didn't stop with Enhertu and here we talk about how the big developments of last year are continuing into 2023. We find out what is coming in each subtype, where there are challenges, and what research is making news right now.Dr. Hamilton is the Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, as well as a partner with Tennessee Oncology PLCC. She currently serves on ASCO's Cancer Research Committee as well as the 2023-2025 Scientific Committee Co-Chair of the ESMO Breast Cancer Meeting.

Discover the Truth About Cancer: Debunking Misconceptions with Dr. Sanjay and Dr. Joseph Zundell. Learn about cancer cell adaptation, comprehensive treatment plans, and new developments in cancer treatments like Enhertu and bispecific antibodies. Also, explore immunotherapy, cancer therapy testing on mice, and personalized treatment options.

You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world's leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses. In this podcast, Cancer.Net Associate Editor Dr. Norah Lynn Henry covers new research in breast cancer treatment, prevention, and survivorship presented at the 2022 San Antonio Breast Cancer Symposium, held December 6-10. Dr. Henry is a Professor and Interim Chief of the University of Michigan's Division of Hematology/Oncology in the Department of Internal Medicine and is the Breast Oncology Disease Lead at the Rogel Cancer Center in Ann Arbor, Michigan. View Dr. Henry's disclosures at Cancer.Net. Dr. Henry: Hi, I'm Dr. Lynn Henry, a breast cancer oncologist from the University of Michigan Rogel Cancer Center. Welcome to this quick summary of updates from the 2022 San Antonio Breast Cancer Symposium. I have no conflicts of interest for any of the trials that I will talk about today. First, I'm going to give a very brief overview of the types of breast cancer, and then talk about some research that was presented on both metastatic and early-stage breast cancer. As a reminder, there are multiple kinds of breast cancer. Some breast cancers are called hormone receptor-positive or estrogen receptor-positive and are stimulated to grow by the hormone estrogen. We treat those cancers with anti-estrogen treatments, which block estrogen or lower estrogen levels. We often combine anti-estrogen treatments with other medications to try to make them work even better against the cancer. Other breast cancers are called HER2-positive. These are often more aggressive cancers, but because they have extra copies of HER2, they often respond to treatments that block HER2. Finally, there are breast cancers that don't have hormone receptors or HER2 receptors. These are called triple-negative breast cancer and are also often fairly aggressive cancers. One of the most exciting takeaways from the San Antonio meeting was the promise of new medications on the horizon to treat hormone receptor-positive, HER2-negative metastatic breast cancer. A commonly used treatment for metastatic breast cancer that is hormone receptor-positive and HER2-negative is fulvestrant, which is a type of medicine called “SERD,” or selective estrogen receptor degrader. At the meeting, we heard new data about 2 new SERD medications: elacestrant that was tested in the EMERALD trial and camizestrant that was tested in the SERENA trial, both of which are oral pills instead of injection medications and both of which may work particularly well against tumors that have mutations in the estrogen receptor called ESR1. In addition, we heard about capivasertib, which is an AKT inhibitor that was shown to work well when combined with fulvestrant and had less toxicity than some of the similar drugs that had previously been tested. For treatment of HER2-positive metastatic breast cancer, there are now a lot of medications that have been FDA approved, so some of the questions that clinical trials are now examining are related to what order we should use the medications in when we are treating patients. We heard about 2 studies of the medication trastuzumab deruxtecan, which I'm going to refer to as Enhertu. This drug is a combination of the anti-HER2 antibody trastuzumab plus a chemotherapy drug, and the antibody targets the drug to a cancer like a guided missile. Enhertu is currently routinely used to treat patients with metastatic HER2-positive breast cancer. We heard updated data that showed that when Enhertu was compared head-to-head against trastuzumab emtansine, also known as Kadcyla, patients who were treated with Enhertu were able to stay on the medication for a lot longer compared to patients who were treated with Kadcyla. We also heard that for patients who had already been treated with Kadcyla but it was no longer working, it is reasonable to switch to treatment with Enhertu at that point, because it is still likely to be effective. These studies may help oncologists decide what order to use these newer medications when treating patients with HER2-positive breast cancer. To switch gears a little bit, I'll now talk about another study I found interesting. This one is in the setting of people who are at high risk of developing breast cancer, but who haven't actually been diagnosed with cancer yet. In general, people are recommended to take either tamoxifen or an aromatase inhibitor medication, which is the same as treatment for patients who have been diagnosed with hormone receptor-positive breast cancer. But in this case, it's trying to prevent them from ever getting breast cancer in the first place. However, many people don't take the medications because they are concerned about side effects. A study was therefore performed in Italy that compared the 5-milligram dose of tamoxifen, which is only one-quarter of the full dose, with placebo for 3 years. After 7 years of follow-up, this low dose of tamoxifen, which is being referred to as “babytam,” was shown to reduce the risk of developing breast cancer by about half, which is similar to the effects seen with the full dose of the medication. Plus, there were fewer side effects. This lower dose is likely to be used regularly for prevention of breast cancer based on these findings, although this lower dose of tamoxifen has not yet been tested to see if it is as effective as the full dose of medication for preventing breast cancer recurrence, so it is not routinely recommended for patients who have a diagnosis of breast cancer to receive this lower dose. Finally, I will touch briefly on exciting results from the POSITIVE trial, which is a trial conducted around the world that examined whether it is safe for young women with hormone receptor-positive breast cancer to stop taking anti-hormone therapy to become pregnant. The women on this trial stopped taking endocrine therapy after taking it for about 18 to 30 months, and then spent up to 2 years trying to become pregnant. About three-quarters of the patients had at least 1 pregnancy during that time, and importantly, there was no increased risk of breast cancer recurrence seen in these patients. Once patients were done with their pregnancy, it was recommended that they restart taking endocrine therapy again. There were a lot of other research findings presented that were related to treatment for both early-stage and metastatic breast cancer at this meeting. Importantly, we got glimpses of the many new drugs on the horizon for treatment of breast cancer, including the 3 that I mentioned already. And we eagerly await the results of large, randomized trials so that the drugs that work can be used to care for patients with breast cancer. But for now, that's it for this quick summary of important research from the 2022 San Antonio Breast Cancer Symposium. Stay tuned to Cancer.Net for future updates from upcoming breast cancer conferences. Thank you. ASCO: Thank you, Dr. Henry. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

2021 results from the DESTINY-Breast03 study showed that Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) more than doubled the 12-month progression-free survival rate compared to Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated. At the 2022 San Antonio Breast Cancer Symposium, Dr. Sara Hurvitz presented new overall survival results, showing that Enhertu also improves overall survival compared to Kadcyla. Listen to the episode to hear Dr. Hurvitz explain: overall survival and progression-free survival results severe side effects of Enhertu how the researchers managed any severe lung problems that developed in people receiving Enhertu

A diagnosis of lung cancer used to be a diagnosis of death. Not anymore.Lung disease caused by a new drug for cancers—including metastatic or advanced breast cancer—can be effectively treated using approaches that focus on early detection and prompt management, according to a study published in ESMO Open in August 2022.Using data from nine clinical trials, this study provides one of the most comprehensive analyses of interstitial lung disease diagnosis and treatment in patients who received an antibody-drug conjugate known as T-DXd, from a class of drugs designed as a targeted therapy for treating cancers.The retrospective review examined 1,150 heavily pre-treated patients with breast, lung, gastric, colorectal, or other cancers across nine studies treated with T-DXd, also known as ENHERTU®.Senior author Charles Powell, MD, MBA, joins us today to discuss the findings. He is the Professor of Medicine and System Division Chief for Pulmonary, Critical Care, and Sleep Medicine at the Icahn School of Medicine at Mount Sinai in New York and the Medical Director of Respiratory Therapy at Mount Sinai Hospital.  He also directs research programs focused on the early detection of lung interstitial disease and airway disease.

A diagnosis of lung cancer used to be a diagnosis of death. Not anymore.A diagnosis of lung cancer used to be a diagnosis of death. Not anymore.Lung disease caused by a new drug for cancers—including metastatic or advanced breast cancer—can be effectively treated using approaches that focus on early detection and prompt management, according to a study published in ESMO Open in August 2022.Using data from nine clinical trials, this study provides one of the most comprehensive analyses of interstitial lung disease diagnosis and treatment in patients who received an antibody-drug conjugate known as T-DXd, from a class of drugs designed as a targeted therapy for treating cancers.The retrospective review examined 1,150 heavily pre-treated patients with breast, lung, gastric, colorectal, or other cancers across nine studies treated with T-DXd, also known as ENHERTU®.Senior author Charles Powell, MD, MBA, joins us today to discuss the findings. He is the Professor of Medicine and System Division Chief for Pulmonary, Critical Care, and Sleep Medicine at the Icahn School of Medicine at Mount Sinai in New York and the Medical Director of Respiratory Therapy at Mount Sinai Hospital.  He also directs research programs focused on the early detection of lung interstitial disease and airway disease.

A diagnosis of lung cancer used to be a diagnosis of death. Not anymore.A diagnosis of lung cancer used to be a diagnosis of death. Not anymore.Lung disease caused by a new drug for cancers—including metastatic or advanced breast cancer—can be effectively treated using approaches that focus on early detection and prompt management, according to a study published in ESMO Open in August 2022.Using data from nine clinical trials, this study provides one of the most comprehensive analyses of interstitial lung disease diagnosis and treatment in patients who received an antibody-drug conjugate known as T-DXd, from a class of drugs designed as a targeted therapy for treating cancers.The retrospective review examined 1,150 heavily pre-treated patients with breast, lung, gastric, colorectal, or other cancers across nine studies treated with T-DXd, also known as ENHERTU®.Senior author Charles Powell, MD, MBA, joins us today to discuss the findings. He is the Professor of Medicine and System Division Chief for Pulmonary, Critical Care, and Sleep Medicine at the Icahn School of Medicine at Mount Sinai in New York and the Medical Director of Respiratory Therapy at Mount Sinai Hospital.  He also directs research programs focused on the early detection of lung interstitial disease and airway disease.

Outubro Rosa é a campanha anual que visa sensibilizar sobre a importância do diagnóstico precoce do câncer de mama, a maior causa de morte em todas as regiões do Brasil, exceto no norte do país.  Taíssa Stivanin, da RFI Neste ano, a data tem um significado especial: após quase três anos de pandemia de Covid-19, ela poderá ser comemorada sem restrições, com eventos previstos em todo o mundo. No Brasil, a estimativa é que a doença tenha provocado 50 mortes por dia no país em 2021, segundo dados do Inca, o Instituto Nacional do Câncer. Em 2020, 685 mil mulheres morreram vítimas do câncer do seio, segundo a OMS (Organização Mundial da Saúde) em todo o mundo. Muitas dessas mortes poderiam ter sido evitadas, já que, se descoberto no início, e dependendo do tipo de câncer, a chance de cura pode chegar a 100%, explicou à RFI o mastologista Fábio Augusto Arruda de Oliveira, do Hospital Sírio-Libanês.  Segundo ele, houve muito atraso nos diagnósticos nos dois primeiros anos da epidemia de Covid-19 e há estudos mostrando que o número de mamografias realizadas diminuiu cerca de 40%. Em 2021, diz, a estimativa é que 1,6 milhão de exames deixaram de ser feitos. “A gente vê no consultório chegarem casos com tumores um pouco maiores, e mais avançados. Aqui no Brasil, e acredito que, no mundo todo, alguns serviços fecharam, literalmente. A mulher não tinha como realizar a mamografia”, diz. O início do monitoramento, ressalta o médico, difere em cada país. “A tendência no Brasil é começar a fazer a mamografia anualmente, a partir dos 40 anos, em casos com o chamado risco habitual. No caso de mulheres com risco maior, por conta de cânceres na família, podemos antecipar um pouco esse início”, explica.  Ele lembra que entre 10 e 15% dos cânceres são genéticos e trazem mutações em genes específicos, como o BRCA1 ou BRCA2. Eles fazem com a que as portadoras tenham 80% de chance de desenvolver a doença. Isso requer o monitoramento mais precoce em função da idade em que a mãe da paciente teve o tumor, por exemplo, explica o mastologista. Riscos inespecíficos Na maior parte dos casos, o câncer do seio aparece sem que haja riscos específicos, mas causas “ambientais”, ligadas ao modo de vida, por exemplo. “São os fatores epigenéticos, que podem influenciar a genética. A célula tumoral é uma célula que teve algum estímulo ruim, gerando uma mutação na sua própria genética. Se essa célula perde sua capacidade de velocidade de crescimento e morte, ela se prolifera muito rápido formando um tumor e gerando um crescimento desordenado.” A forma como isso vai acontecer constitui um dos grandes mistérios da Medicina e a genética individual ainda é um vasto campo a ser estudado. Em todos os casos, o prognóstico do câncer depende sempre da prevenção, que melhorou nos últimos anos com o avanço dos métodos de diagnóstico. Um exemplo é a tomossíntese, ou mamografia 3D, que permite uma análise profunda e detalhada da mama. A tecnologia usada, associada a novos medicamentos, faz com que o câncer do seio tenha deixado de ser uma sentença de morte.  “De forma geral, temos uma taxa de cura que ultrapassa 90% ou 95%. Quando você diagnostica um tumor pequeno, de tamanho milimétrico, chega a 100% de cura”, ressalta o especialista. Caso o tumor seja detectado num estágio mais avançado, com linfonodos ou metástases, a expectativa de cura ou sobrevida diminui em função do avanço da doença.  Existem vários tipos de cânceres do seio. Após a descoberta do tumor é necessário analisar, por exemplo, os receptores hormonais, a presença ou a ausência da proteína HER2 na superfície das células, além da velocidade de proliferação. Essas informações, ressalta o mastologista, determinam o tratamento e mostram se o câncer será mais ou menos agressivo.  Quanto menor for o tumor, maior é a possibilidade de recorrer a tratamentos que serão menos agressivos ou mutilantes. “O mais comum é o carcinoma invasivo, que pode ser ductal, e representa 80% dos casos, ou lobular. Esses são os cânceres de mama. Mas nas mamas também existem sarcomas e, agora, os linfomas induzidos pela prótese de silicone”, salienta. Novas moléculas descobertas recentemente também trazem esperança. Uma delas é a transtumuzab deruxtecan (nome comercial do Enhertu), que pode ser usada em casos específicos: pacientes, por exemplo, com a proteína HER2 produtiva e metástases. De um modo geral, o tratamento é modulado em função do caso, mas se baseia na cirurgia, quimioterapia e radioterapia. A quimioterapia pode ser realizada antes da operação e a imunoterapia também vem sendo utilizada, em protocolos mais avançados. Prevenção é desigual no país No Brasil, infelizmente as chances de cura e os tratamentos disponíveis diferem em função do atendimento, explica o mastologista, que conviveu de perto com o problema da desigualdade em sua carreira.  O agendamento da mamografia é mais difícil no SUS (Sistema Único de Saúde) e a qualidade dos equipamentos é inferior, explica o especialista, que atuou durante vários anos em hospitais públicos. Além disso, há demora no agendamento da consulta, do exame e na obtenção dos resultados.  “Eu briguei durante muitas vezes na unidade onde eu trabalhava porque eu não aceitava que demorasse 60 dias o resultado de uma biópsia. A resposta é que era o contrato. Então tem que mudar o contrato. A gente não pode aceitar e ficar satisfeito com uma resposta dessas”, reitera o especialista. Ele também lembra que o acesso influencia no diagnóstico precoce e na sobrevida, apesar da situação, em geral, ter melhorado. “Mulheres que trabalham muito, acordam de madrugada, pegam a condução, trabalham o dia inteiro e chegam em casa muito tarde, têm dificuldade para fazer o exame e negociar com o patrão. A gente tem um perfil com doença mais avançada de quem usa saúde pública, em relação a quem usa complementar”, resume.

The biggest news out of the June meeting of the American Society of Clinical Oncology (ASCO) was the success of a relatively new drug called Enhertu (trastuzumab deruxtecan) in treating estrogen positive (ER+) and triple negative (TNBC) breast cancers that were also HER2 low. Results of the clinical trial presented at the meeting were so positive that in August the FDA approved the drug for patients with metastatic HER2 low breast cancer that has progressed on other treatments.Most of us likely learned our cancer's positive or negative HER2 status when we were diagnosed. But how can you find out if you're HER2 low? And what does this mean for treatment? In this episode, pathologist David G. Hicks MD, Professor and Director of IHC-ISH Laboratory Breast Subspecialty Service at the University of Rochester, and Maryam Lustberg MD, MPH, Director of the Center for Breast Cancer at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center, help the Our MBC Life team understand HER2 low and what it means for treatment.Spoiler alert: In its Phase III clinical trial, Enhertu significantly extended both progression-free survival and overall survival versus standard of care chemotherapy—an outcome that earned its research team a standing ovation at ASMO. However, the drug has significant side effects, and Our MBC Life's Natalia Green shares her experience with her own treatment.ResourcesDavid G. Hicks, MD bio -  www.urmc.rochester.edu/people/20643669-david-g-hicksMaryam Lustberg, MD, MPH - https://medicine.yale.edu/profile/maryam_lustberg/Newly published by Dr. Hicks: https://www.sciencedirect.com/science/article/abs/pii/S0740257022000570The official press release from ASCO re Enhertu: https://www.asco.org/about-asco/press-center/news-releases/novel-antibody-drug-conjugate-doubles-progression-free

At the European Society for Medical Oncology Congress 2022, Dr. Naoto Ueno presented patient-reported quality-of-life outcomes from the DESTINY-Breast04 study, which found that compared to doctors' choice of chemotherapy, Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer. Listen to the episode to her Dr. Ueno explain: how the researchers assessed quality of life the results showing that Enhertu offered better quality of life than the doctors' choice of chemotherapy differences in side effects between Enhertu and chemotherapy

Listen to a soundcast of the 8/10/2022 and 8/11/2022 FDA approvals of Tabrecta (capmatinib) for metastatic non-small cell lung cancer, and Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic non-small cell lung cancer.

Listen to a soundcast of the 8/5/2022 FDA approvals of Enhertu (fam-trastuzumab deruxtecan-nxki) for patients unresectable or metastatic HER2-low breast cancer, and Nubeqa (darolutamide) for adult patients with metastatic hormone-sensitive prostate cancer.”

Here are the links for everything discussed in Episode 76. Times are also below so feel free to skip around and get to the updates that interest you.  (1:32) FDA issues EUA for JYNNEOS vaccine (5:05) FDA approves Enhertu for NSCLC w/ HER2 expression Other FDA approvals: (8:13) - Myfembree (8:43) - Nubeqa (9:08) - Calquence (9:36) - Xofluza CDC website for COVID information - get boosted!FDA monkeypox response websiteConnect with The Rx Daily Dose:Twitter      Instagram      YouTube      Linkedin       WebsiteEmail: therxdailydose@gmail.comConnect with Ian Parnigoni PharmD. on social media:Twitter       Instagram       Linkedin  ★ Support this podcast on Patreon ★

In this episode, Ayesha discussed a new COVID-19 test technology that Innova Medical Group, world leader in at-home COVID-19 tests, has reached a licensing deal for with the University of Birmingham where the technology was developed. The new test is as sensitive and accurate as PCR tests and faster than lateral flow (rapid antigen) tests. Hear about the innovative new technology underlying the molecular test, and how the test is also being developed for the detection of other viruses. Ayesha also talked about the FDA approval of AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) Enhertu (trastuzumab-deruxtecan) for the treatment of patients with unresectable or metastatic HER2-low breast cancer. The approval makes Enhertu the first approved drug for this indication. Find out about the trial data that led to the approval and its effectiveness in HER2-low breast cancer, which is a newer subtype of the cancer.Read the full articles here: Innova Secures Licensing Rights for U of Birmingham's New COVID-19 Test Technology RTF-EXPARAstraZeneca's Enhertu Gets FDA Approved as First Therapy for HER2-Low Breast CancerFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. In the Research Round Up series, ASCO experts and members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field and explain what it means for people with cancer. In today's episode, our guests will discuss new research in multiple myeloma, breast cancer, and cancer in adults 60 and over that was presented at the 2022 ASCO Annual Meeting, held June 3-7. First, Dr. Sagar Lonial discusses a study on treatment for newly-diagnosed multiple myeloma in people under 65.   Dr. Lonial is a professor of Hematology and Medical Oncology at Winship Cancer Institute at Emory University, where he also serves as Department Chair. He is also the Cancer.Net Associate Editor for Myeloma. View Dr. Lonial's disclosures at Cancer.Net. Dr. Lonial: Hello, I'm Dr. Sagar Lonial from the Winship Cancer Institute of Emory University in Atlanta, Georgia. And today I'm going to discuss one of the Plenary abstracts at ASCO 2022, which was the DETERMINATION study, again, presented at the ASCO Annual Meeting. For the sake of disclosure, I just want to make sure I list that I was an investigator on this study. I also have consulting relationships with Takeda, Celgene, BMS, Janssen, and other companies that have agents in the context of multiple myeloma. So the reason I want to talk about this study today is I think it's a really important study that was designed over a decade ago to really ask the question, with a really powerful induction regimen that uses what we now call the RVd regimen, lenalidomide with bortezomib and dexamethasone, do you really still need to have high-dose therapy and autologous transplant as part of the treatment approach? And so the trial was a very simple randomized trial that everybody received RVd induction. And then there was a randomization between early transplant and then going on to consolidation and continuous lenalidomide maintenance versus no transplant going on to consolidation and lenalidomide maintenance. So both arms actually received continuous lenalidomide maintenance, which is really one of the important endpoints of this study overall. And the reason I say that is there was a smaller study done in France a few years previous to this where patients only received 1 to 2 years of lenalidomide maintenance. And in that trial, clearly the use of transplant was better. And the remission duration for the group that received the transplant was about 48 months. So the question was, with continuous lenalidomide maintenance, can you make that longer? So randomized trial, over 600 patients were randomized between these 2 arms. And the follow-up now is somewhere around 7 years in total. And what was demonstrated both in the ASCO Annual Meeting as well as in the paper that came out at the same time in the New England Journal of Medicine was that the remission duration was clearly longer in the group that had the transplant than the group that did not, even with both arms receiving continuous lenalidomide maintenance. And it was almost 66 months in the group that received the transplant, 21 months longer, almost 2 years longer than the group that did not receive the transplant. And so I think this is really important because what it says is that even in an era of really good induction therapy, transplant continues to offer significant benefit in terms of progression-free survival. Now, the reason progression-free survival is so important in this study is that we know that no time is more sensitive for treatment of myeloma than that first time we treat the patient. And so prolonging that first remission is really important because the disease is at its most sensitive at that time point. Now, there were questions about overall survival. Should we see an overall survival benefit? And I'll tell you, A, this trial was never designed to measure an overall survival benefit. And, B, the median survival for myeloma patients is now between 10 and 15 years on average. And so with only 7 year follow-up, it seems to me unrealistic to expect this to have a survival benefit at this early time point. So rather than saying there's no difference in overall survival, I think it's a fair statement to say at the short follow-up we have, there is no difference in survival. But I actually don't think survival is the right endpoint for newly diagnosed myeloma trials in fit patients because we do have so many important treatments to discuss. Now, there was also discussion about adverse events. Obviously, the quality of life during the transplant dropped a little bit. Not a big surprise. That lasted about 2 to 3 weeks, and then quickly, by 3 months out, returned back to baseline for almost every patient in the study. Additionally, there was a concern about second primary malignancies. If you look at this data, it's really no different than what we saw in the French study. There was a slightly higher risk of second primary malignancy, but we know that this is the case not only in myeloma, but in patients who receive alkylate-based therapy. And despite that, the progression-free survival was 2 years longer in the group that received the transplant than the group that did not. So I think, in summary, this is really an important trial because there are many groups that are making the case that perhaps we don't need transplant in this modern era of myeloma therapy. And I think that it's important to recognize that what we're looking at are not short-term endpoints. We're not looking at early MRD (minimal residual disease) negativity. What we're looking at is really ultimate measurement of clinical benefit, which to me is prolonging that first remission as long as you can. And so this trial clearly demonstrates that for young, fit patients, transplant continues to offer significant benefit, almost 2 years of benefit with continuous lenalidomide maintenance. And while there's a push to say perhaps we can think about which patients may or may not need a transplant, honestly, as clinicians, we're not good enough to make that prediction. And what I think is really important is that we not lose sight of trying to prolong that first remission with the best tools that we have. And I think even in this modern era of 2022, high-dose therapy and autologous transplant continues to be one of those tools, and we want to use it to maximize the duration of that first remission. So thank you again for listening to this brief summary of the DETERMINATION trial presented at the 2022 ASCO Annual Meeting and published in the New England Journal of Medicine. ASCO: Next, Dr. Norah Lynn Henry discusses new treatment advances for people with metastatic breast cancer, as well as 2 studies in early-stage breast cancer. Dr. Henry is an Associate Professor in the University of Michigan's Division of Hematology/Oncology in the Department of Internal Medicine and is the Breast Oncology Disease Lead at the Rogel Cancer Center. She is also the Cancer.Net Associate Editor for Breast Cancer. View Dr. Henry's disclosures at Cancer.Net. Dr. Henry: Hi. I'm Dr. Lynn Henry, a breast cancer oncologist from the University of Michigan Rogel Cancer Center. Welcome to this quick summary of updates in breast cancer from the 2022 ASCO Annual Meeting. I have no conflicts of interest for any of the trials that I will talk about. First, I'm going to give a very brief overview of the types of breast cancer, then talk about some research that was presented on both metastatic and early-stage breast cancer. As a reminder, there are multiple kinds of breast cancer. Some breast cancers are called hormone receptor-positive or estrogen receptor-positive and are stimulated to grow by the hormone estrogen. We typically treat those cancers first with antiestrogen treatments, which block estrogen or lower estrogen levels. Other breast cancers are called “HER2 positive.” These are often more aggressive cancers, but because they have extra copies of HER2, they often respond to treatments that block HER2. Finally, there are breast cancers that don't have hormone receptors or very much HER2. These are called triple-negative breast cancer and are also often aggressive cancers. One of the biggest stories from the ASCO Annual Meeting was the results of the DESTINY-Breast04 trial. In this trial, researchers studied a type of medication called trastuzumab deruxtecan, which is also called Enhertu. This drug is a combination of the anti-HER2 antibody, trastuzumab, plus a chemotherapy drug, and the antibody targets the drug to the cancer sort of like a guided missile. Trastuzumab deruxtecan is currently routinely used to treat patients with metastatic HER2-positive breast cancer. Now, the interesting thing is there was already data from studies that suggested that this drug might also work against breast cancers that have some HER2 receptors on the surface of their cells, but not so many that they meet the true definition of being HER2 positive. For the DESTINY-04 study, patients' tumors had to have either 1+ or 2+ HER2, which some people called “HER2 low,” and could be either estrogen receptor positive or negative. Two thirds of the patients were treated with trastuzumab deruxtecan, and the other one-third were treated with 1 of 4 different standard chemo regimens that their physician thought was the best treatment option for them. Treatment with trastuzumab deruxtecan was shown to lengthen the time people were able to remain on treatment. Importantly, it was also shown to increase the overall survival of patients compared to standard chemotherapy by more than 6 months for patients with estrogen receptor-positive cancer and by more than 10 months for patients with estrogen receptor-negative cancer. Since this is a drug that we currently use to treat patients with other types of cancer, we actually know a lot about its side effects. One key toxicity is it can cause a very severe inflammation of the lungs in a very small subset of patients. So this is something that we have to watch for very carefully. Otherwise, it is a relatively well-tolerated drug, especially compared to standard chemotherapy. The main side effects are nausea and fatigue. Another clinical trial presented at ASCO called TROPiCS-02 also studied a drug that is currently used to treat a different type of breast cancer. In this case, the drug is sacituzumab govitecan, also called Trodelvy. It is also a combination of an antibody that is targeted against cancer cells plus a chemotherapy drug. Sacituzumab govitecan is currently approved to treat metastatic triple-negative breast cancer. In the TROPiCS-02 trial, however, it was tested to see how effective it is for treating hormone receptor-positive, HER2-negative metastatic breast cancer. All of the patients enrolled in this trial had already been treated with antihormone therapy medications as well as at least 2 chemotherapy regimens. Half of the patients were randomized to treatment with sacituzumab govitecan, and the other half were treated with 1 of 4 standard chemotherapy drugs that their physician thought was the best for them. Those patients who were treated with sacituzumab govitecan had a longer time on average that the treatment worked compared to those who received standard chemo. They also had improved quality of life based on responses that the participants themselves provided on questionnaires. Although the overall benefit was rather modest, this drug may represent a new treatment option for patients with hormone receptor-positive, HER2-negative metastatic breast cancer, although at this time it isn't yet approved for treatment of this type of breast cancer. Both of these are examples of being able to take drugs that have been shown to treat 1 type of cancer and potentially expand it so that they can be used to benefit more patients with breast cancer. These drugs are also being tested to see if they are beneficial for treating early-stage breast cancer. So we await more hopefully very exciting results in the future. To switch gears a little bit, I'll now talk about another study I found interesting. This one is in the setting of early-stage breast cancer. So typically, radiation therapy is recommended after lumpectomy since it reduces the likelihood of cancer returning in the breast. However, questions have arisen about how much benefit radiation is actually providing for some patients whose risk of having cancer return in the breast is really low to start with. Therefore, these patients may be at risk of the side effects of radiation as well as other risks, such as financial problems, without actually getting much benefit from the treatment. Therefore, this trial, called LUMINA, evaluated whether radiation therapy was beneficial after lumpectomy for patients who have small, low-risk breast cancers and no lymph node involvement. The trial included 500 women who were at least 55 years of age with invasive ductal cancers that were no more than 2 centimeters in size. They had to be estrogen receptor-positive, HER2-negative, either grade 1 or 2, and Ki-67 low. Everyone had to be planning to take antihormone therapy for at least 5 years. During the 5-year follow-up period, a total of 10 patients out of 500, about 2.3% of all patients, had their cancer return in the breast. The researchers therefore concluded that for patients with this type of very low-risk breast cancer, it is reasonable to omit radiation therapy and just take endocrine therapy. Similar results have previously been shown for patients over the age of 70 with small lymph node-negative low-risk cancers, but this trial expands that option to patients who are as young as 55. Finally, I will touch briefly on the updated results from the ABCSG-18 clinical trial. So this trial enrolled postmenopausal women with early-stage estrogen receptor-positive breast cancer who are being treated with aromatase inhibitor therapy. Aromatase inhibitors are known to cause reductions in bone density. This trial therefore evaluated a medication called denosumab, also called Prolia, which is used to treat osteoporosis. Participants were randomized to treatment every 6 months with either denosumab or a placebo. They found that the patients who were treated with denosumab were half as likely to have a bone fracture. Importantly, patients treated with denosumab also had an improvement in bone density despite taking the aromatase inhibitor medicine, whereas those who received placebo had a decrease in their bone density over time. The other very interesting thing from this study is that patients who received treatment with denosumab were less likely to have their breast cancer return or to develop a new cancer during the 8-year follow-up period. So it's actually already recommended that postmenopausal patients with all types of early-stage breast cancer consider treatment with a different type of bone strengthening medicine called a bisphosphonate as part of their breast cancer treatment. The goal is to further reduce their risk of cancer returning. These new results will now lead experts to debate whether to also include denosumab as a potential additional breast cancer treatment option, not just to help protect people's bone density. There were a lot of other research findings presented that were related to treatment for both early-stage and metastatic breast cancer at the meeting. Importantly, we got glimpses of the many new drugs on the horizon for treatment of breast cancer, and we eagerly await the results of large, randomized trials so that the drugs that work can be used to care for patients with breast cancer. But for now, that's it for this quick summary of important research from the 2022 ASCO Annual Meeting. Stay tuned to Cancer.Net for future updates from upcoming breast cancer conferences. Thank you. ASCO: Thank you, Dr. Henry. Finally, Dr. Shakira Grant discusses 3 studies that looked at cancer in people 60 or older. This field is also known as geriatric oncology. Dr. Grant is an Assistant Professor in the Divisions of Hematology and Geriatric Medicine at the University of North Carolina at Chapel Hill and a board-certified Geriatric Hematologist/Oncologist. View Dr. Grant's disclosures at Cancer.Net. Dr. Grant: Hi, everyone. I am Dr. Shakira Grant. And I'm an assistant professor at the University of North Carolina at Chapel Hill. I'm also a clinician scientist with a focus on social disparities and how they influence the health and aging of older adults with cancer, primarily multiple myeloma. And for today's talk, I have no relevant conflicts of interest to disclose. It's such a pleasure to be able to talk today about the ASCO 2022 geriatric oncology and presenting key studies, which I believe were really practice-changing or really set up the foundation for informing future research directions. And to start us off, I wanted to start us with abstract 12012 by Dr. Mackenzie Fowler. And this was presented based on the University of Alabama at Birmingham's actual research group. And the title of their presentation was “Rural-Urban Disparities in Geriatric Assessment Impairments and Mortality Among Older Adults with Cancer.” And this was the result of a large registry study, predominantly patients with gastrointestinal cancer-- so cancers such as liver cancer, colon cancer. And what the authors really wanted to do here was to explore if whether or not living in a rural location, for example, is associated with having an impairment based on what people report in their ability to function at home, their quality of life. And they also wanted to see whether or not where you live, meaning a rural location, whether that can be associated with how long you are expected to live or your overall survival. So this was really a study that took patients who were truly older. There were patients who were above the age of 60. As I mentioned, these were patients predominantly with cancers of the liver, the colon, and the pancreas. And patients completed a baseline, what we call a geriatric assessment, to try to assess their overall or global health. And on these assessments, patients are asked questions about how they would rate their physical function and their quality of life. And what the authors found here is that in general, when patients lived in rural areas, this was associated with patients self-reporting more functional deficits, meaning that they reported that they had impairments in the ability to function at home from a physical perspective. They also had impairments in quality of life—so how you rate your general life and how you're doing from a day-to-day basis. And this was impaired if you lived in a rural residence. And then, importantly, this study also showed that living in a rural location—and, again, this study was centered in Alabama—that that was also associated with a reduced overall survival, meaning that people were found in rural areas to live a shorter life with these cancers compared to those who live in non-rural places or, as we call it, urban. And I think why I chose this particular study is because it's one of the first studies using a large data set of almost 1,000 patients that they have enrolled and really looking at the idea of the physical environment, so where a person lives, and how that really interacts with everything else to influence the health of an individual. And this study, I believe, really lays the foundation for an area of work in geriatric oncology where we are moving away from just thinking about the older adult, but we're also thinking about the older adult and the other identities. So we're really considering the sociocultural influence. So we think about race. We think about socioeconomic status, income. But now, we're also including the physical environment. And that is where people are living and spending the majority of their time. And that is in this study classified as rural-urban residency. So for this study, overall, I would say that this is really moving the field forward in a direction where we're moving away from just looking at just older adults, but we're thinking about older adults and all of the other stressors that they face, especially when they live in the community and how that impacts their health. The next study that I wanted to highlight was a study that was performed by Dr. Heidi Klepin at Atrium Health, Wake Forest Baptist. And this was a study that looked at evaluating the association between an electronic health record-embedded frailty measure and survival among patients with cancer. Again, this was an older adult population. It was just over 500 patients involved, and patients were over the age of 65. They had a new diagnosis of the most common cancers, which are lung cancer, colon cancer, and breast cancer. And the good thing about this particular study is that it sought to use data that is readily captured in the electronic health record to characterize a patient as fit, prefrail, and frail. So why is that important for the geriatric oncology community and even beyond is when we're dealing with older adults, we're always thinking about ways in which we can actually characterize their fitness and their ability to hence tolerate their therapies, being chemotherapy, and how likely they are to die if they're having these functional impairments. And so importantly, what this study showed was that in their sample, they found that up to 17% of people were characterized as frail using this index. And the significance of this finding is that when they looked at how long people were likely to live with these cancers, breaking it down according to if you were fit, prefrail, or frail, those who were frail had the shortest overall survival. So it means the time from which they were diagnosed until they die was much shorter than any of the other categories. And that equated to a difference between those who were fit and those who were prefrail of 10 months for those who were frail for overall survival and more than 54 months for those who were actually considered to be fit. So this is really, really important because what we are seeing is that if you are really fit, you are living on average with these cancers—the overall survival, at least for their institution, was more than 54 months. But then as you move across that spectrum of fitness, we're actually seeing that your survival decreases significantly. And so why is this important? So this is important because it's one of the first studies that is actually looking to operationalize the frailty measure for us to be able to potentially use and adapt into other health systems using data that we already collect. So it's no longer burdensome on patients to try to fill out additional forms or for other staff to be involved and collect this data. And this data is showing us that there is an association with this particular frailty index and the ability to predict overall survival-- so, again, a critical study in the geriatric oncology population looking at patients with the 3 most common types of cancer, which are lung cancer, colon cancer, and breast cancer, and really showing us that there is a way potentially to operationalize how we characterize the fitness level of an older adult and then using that data not just to say, "Yes, this person is frail," but for us in real-time to see results where we can see that there is a significant difference in terms of overall survival. Importantly, this is going to be a study where we continue to watch closely the developments over the next few years, especially as the authors and the research team note that their next steps involve looking at how to study how these frailty measures, or the frailty scores that people get when they come in and they're at baseline, how this changes throughout the course of treatment. And that has a lot of implications because now, we have the potential to start thinking about using a frailty-adapted approach to caring for older adults with cancer. What that means is when you're getting your treatment and we are following these scores, as we see things changing, this may be an indicator to us that, "Hey, we need to make some modifications in response to these frailty measures to make sure that our older adult population is able to tolerate their chemotherapies and have maximum benefit while also enjoying a good quality of life." So finally, I want to highlight this third study. And this was a study that was presented by Dr. Etienne Brain. And. Dr. Etienne Brain was also this year's B.J. Kennedy Award recipient. And each year ASCO recognizes the B.J. Kennedy Award recipient as an outstanding investigator who has made significant contributions in the area of research and clinical care of older adults with cancer. In this particular study, Dr. Etienne presented on behalf of his team the final results from a study that was looking at using endocrine therapy with or without chemotherapy for older adult women, so characterized as those who were over the age of 70, with a diagnosis of estrogen receptor-positive, HER2-negative breast cancer. And the importance for this study is that the question they sought to examine was whether or not patients who are in this age range still derive a benefit from receiving chemotherapy in addition to endocrine therapy. And what this study really showed is that there was no survival difference. Meaning when they looked at the data for 4 years, those who got chemotherapy plus endocrine therapy lived just as long as those who also just got endocrine therapy alone. And why this is important is because when you think about giving chemotherapy to an older adult population, as oncologists, we are always weighing the risks and the benefits associated with treatment. So we're always thinking about how tolerable is this drug likely to be? We want to minimize side effects because, at the end of the day, our goal is to treat the cancer, but we also want to focus in on the outcomes that matter most to the older adult population. And in general, these are things like maintaining your mobility, maintaining your mentation, maintaining good quality of life. And so we really want to make sure that we're balancing those risks. And this is why this particular study showing that with chemotherapy or without chemotherapy added to endocrine therapy, there seems to be no survival difference. This could be a way in which we move the field forward in thinking about a select group of patients with breast cancer and whether or not those patients truly need that extra toxicity or burden associated with using chemotherapy or whether endocrine therapy is enough. So with that, I will say across these 3 studies, even though they study different things-- we saw 1 study that looked at the intersectionality between older adults in terms of their chronological age but now starting to examine the influence of physical or social context and how that influences the health and outcomes for individuals with primarily gastrointestinal cancer. We also looked at the development of an electronic frailty index in patients with 3 most common solid tumors - lung cancer, colon, and breast cancer - and found that by using this frailty index collecting readily available data, that there was an association with predicting overall survival. And we saw that those who were characterized as frail had one of the shortest overall survivals. And then finally, in this study, looking at endocrine therapy alone versus chemotherapy and endocrine therapy, we saw that there was no survival difference again in an older adult population. And so what we are seeing here is a theme emerging as the importance of comprehensive evaluations of older adults and the importance also of these measures, when integrated across the research continuum, that they are useful in terms of predictive prognostic abilities and really lay the foundation for future research. So with that, I want to thank you for your time and thank you for listening. ASCO: Thank you, Dr. Grant. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

At the recent 2022 American Society of Clinical Oncology Annual Meeting, researchers presented results showing Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki), which is a type of medicine doctors call an antibody-drug conjugate, improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer. Listen to the podcast to hear Dr. Wojciechowski explain: what HER2-low breast cancer is how Enhertu works how the results of the DESTINY-Breast-04 study will change practice

In the inaugural Twitter Spaces edition of the Oncology Peer Review On-The-Go podcast hosted by CancerNetwork®, Paolo Tarantino, MD, a clinical research fellow at Dana-Farber Cancer Institute, and Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women's Cancer at Dana-Farber as well as an associate professor of medicine at Harvard Medical School, reviewed presentations in breast cancer research from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.  During the live event, Tarantino and Tolaney discussed the phase 3 DESTINY-Breast04 trial (NCT03734029), of fam-trastuzumab-nxki (Enhertu) vs chemotherapy for patients with HER2-low, hormone receptor–positive metastatic breast cancer. The co-hosts also reviewed surprising results from phase 3 PALOMA-2 trial (NCT01740427), which failed to show an overall survival benefit with use of palbociclib (Ibrance) plus letrozole in patients with estrogen receptor–positive/HER2-negative advanced breast cancer vs letrozole alone.  Additionally, Tolaney discussed her presentation of the phase 3 monarchE trial (NCT03155997) that explored adjuvant abemaciclib (Verzenio) in patients with hormone receptor–positive, HER2-negative, node-positive high-risk early breast cancer.  Overall, both investigators said they enjoyed coming back to in-person conferences and how they hope the trend of practice-changing trials continues with future conferences.  Don't forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Another ASCO and more CAR-T data. Arcellx presented early results on its multiple myeloma therapy at last weekend's ASCO annual meeting, and we dig into what it would take to stand up to J&J's Carvykti. But that's not all. People were on their feet for the Enhertu breast cancer drug and its unheard-of results. We've got a lot to share about ASCO. Also under discussion is Fierce's special report on the rising stars in the medtech and healthcare fields and what they have in common. Lastly, we finally have boots-on-the-ground at an industry conference. Our reporter headed out to the first in-person ASCO since the pandemic started. She planned to learn about new data releases and discoveries, and also found out something surprising about herself.  To learn more about the topics in this episode:  Fierce Healthcare and Fierce Medtech's 17 rising stars in health tech ASCO: AstraZeneca, Daiichi's Enhertu could transform breast cancer treatment with landmark HER2-low show ASCO: Gilead's Trodelvy limps forward in new breast cancer lane as below-par showing casts doubt ASCO: ‘Any way you slice' it, Arcellx's CAR-T is matching J&J-Legend's Carvykti, analyst says ASCO: Medidata links CAR-T's cytokine release syndrome risk to common biomarkers in new study ASCO: Black breast cancer patients want to participate in trials, but adequate information is hard to come by Emergent says J&J owes up to $420M for breach of contract. J&J: You want to talk breaches? ADA: Eli Lilly's stellar tirzepatide weight loss data tee up showdown with Novo Nordisk's Wegovy, analysts say ADA: With promising long-term data for its artificial pancreas, Medtronic aims to fully close the diabetes management loop UPDATE: Bristol Myers strikes up Roche rivalry with $4.1B Turning Point buy Eli Lilly wins key dispute over patient warnings in era of DTC advertising ASCO: Return to in-person 'zoo that it always was,' with added COVID challenges—and bad shoes The Top Line is produced by senior multimedia producer Teresa Carey with editor-in-chief Tracy Staton, managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists.  See omnystudio.com/listener for privacy information.

On this episode, PrecisCa speaks with Dr. Sara Hurvitz, medical oncologist & the Director of Breast Oncology at the David Geffen School of Medicine at UCLA. Dr. Hurvitz answers the following: What are the biggest advances in breast cancer in 2021? What is your current approach to metastatic triple negative breast cancer? How do you choose between CDK4/6 inhibitors in both the curative and metastatic settings? How do you treat metastatic HER2 positive breast cancer with organ dysfunction through various lines of therapy? Did we learn any new information about T-DXD (Enhertu) in 2021? How do you envision the future development of T-DXD (Enhertu)? Sara A Hurvitz, MD, is Professor of Medicine at the University of California, Los Angeles (UCLA); co-director of the Santa Monica-UCLA Outpatient Oncology Practice; Medical Director of the Clinical Research Unit of the Jonsson Comprehensive Cancer Center at UCLA; and Director of Breast Oncology. Dr. Hurvitz received board-certification in internal medicine, hematology, and medical oncology. Dr. Hurvitz has won numerous awards over the past few years, among them the Marni Levine Memorial Breast Cancer Research Award 2008 through 2015. Visit www.precisca.com for more resources, content, and access to our entire catalogue of educational content. There you will have access to our complete library of educational videos. New episodes of the PrecisCa Oncology Podcast are released weekly. Please consider sharing our podcast, subscribing & turning on notifications to be the first to know about new releases. Together, we can raise the level of cancer care from diagnosis to recovery.

 Stellar ASCO data for Enhertu show how there's “massive ground” that can still be covered and improved upon by applying new modalities against older targets, said Editor in Chief Simone Fishburn on the latest edition of BioCentury This Week. Fishburn and the BioCentury podcast team dig into the data for antibody-drug conjugate Enhertu from AstraZeneca and partner Daiichi Sankyo for previously treated HR-positive, HER2-negative breast cancer patients. They also assess how new modalities are breathing fresh life into HER3 and explore the themes raised by Fishburn in her conversation with Richard Pazdur, and some of his FDA colleagues at the American Society of Clinical Oncology conference in Chicago. The team also discusses the latest cut of data for tofersen from Biogen in SOD1-mutant amyotrophic lateral sclerosis. 

Listen to a soundcast of the 5/4/2022 FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for adult patients with unresectable or metastatic HER2-positive breast cancer.

Dr. Sara Tolaney is chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women's Cancers at the Dana-Farber Cancer Institute, as well as associate professor of medicine at Harvard Medical School. The 2021 San Antonio Breast Cancer Symposium featured four days of presentations on the latest research on breast cancer. Dr. Tolaney joined us to discuss the research that is most immediately applicable to people who've been diagnosed with the disease. Listen to the episode to hear Dr. Tolaney explain: results of an early study looking at how effective the experimental medicine datopotamab deruxtecan was in treating metastatic, triple-negative breast cancer a study comparing Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) to Kadcyla (chemical name: T-DM1 or ad-trastuzumab emtansine) for metastatic, HER2-positive breast cancer that had spread to the brain the studies that she thinks are practice-changing

Welcome to this episode of Physician's Weekly Podcast. My name is Dr Rachel Giles, from Medicom Medical Publishers, in collaboration with Physician's Weekly. We have 3 fantastic in-depth interviews for you this week. In this 30th episode of the Physician's Weekly Podcast, we speak with Dr Raman Muthsamy from UCLA, about a surgery-free and medicine-free approach to treat gastroesophageal reflux disorder (GERD), called transoral incisionless fundoplication (TIF) which can have durable results. Also in this episode, we speak with our regular contributor who goes by the pseudonym Dr MedLaw, about what a “jury of peers” might mean for a doctor testifying. As she points out, it will be unlikely that there will be anyone with medical knowledge on that jury, so what then?But first, Physician's Weekly speaks with Dr Rupert Bartsch from Vienna, Austria about their recently presented research in treating brain metastases in HER2-positive breast cancer with antibody-drug conjugate trastuzumab deruxtecan. This is our last segment on breast cancer in recognition of October being Breast Cancer Awareness Month. Enjoy listening!Let us know what you thought of this week's episode on Twitter: @physicianswkly Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com! Thanks for listening!

Dr. Brian Wojciechowski practices medical oncology in Delaware County, Pennsylvania at Riddle, Taylor, and Crozer hospitals and also serves as Breastcancer.org's medical adviser. A native of South Philadelphia, he trained at Temple University School of Medicine and Lankenau Medical Center. Dr. Wojciechowski is a sought-after speaker on the topics of medical ethics and the biology of cancer. Dr. Wojciechowski joined us to talk about some of the most notable research at the European Society for Medical Oncology Congress 2021. Listen to the episode to hear Dr. Wojciechowski explain: what an antibody-drug conjugate is results from the DESTINY-Breast03 study, showing Enhertu more than doubled the 12-month progression-free survival rate compared to Kadcyla in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated results from the BrighTNess study, showing adding carboplatin to chemotherapy before surgery improves progression-free survival. Running time: 14:09

La comunidad médica celebra el éxito de los ensayos clínicos del medicamento Enhertu para el tratamiento contra el cáncer de seno, que actualmente se encuentra en tercera fase.La comunidad calificó de "revolucionarios" los resultados obtenidos y una esperanza para las personas que sufren esta enfermedad.El medicamento ha demostrado una eficacia del 72% y no tiene los efectos devastadores de otros tratamientos contra esta enfermedad.

Pinktober is almost upon us, and…ya know, we don't care if you relax with a Mike's Hard Lemonade For The Cure™️, but you should know the truth about Susan G. Komen. First, though, join us for a quick bummer chat. We've all lost friends to this dumb disease. It's what makes cancer so scary, after all—for some of us, it's deadly. Are the unique connections we make with other cancer people worth it when you know their friendship might be a limited time offer? Obviously, we say yes. Then, it's back to Susan G. Regulators, mount up! Questionable partnerships, research funding that doesn't fund much, and pink ribbon lawsuits? We'd rather put our money toward ACTUALLY fighting breast cancer,  or at least helping breast cancer patients directly. Now that Komen & friends have made us all super “aware,” can we order a side of cancer cures? Or even some education and prevention plz?? Preferably with less sexism and commodification, and with some gender inclusion?? PROMISE ME! Then, RATS would like you to meet Enhertu, the rising star for HER2 posi babes. A reduced risk of progression might be your DESTINY. To read more about the RATS in this episode: https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-head-to-head-trial-meets-primary-endpoint.htmlFor Gayle Sulik's inteview, visit Vox: https://www.vox.com/the-goods/2018/10/17/17989624/pinkwashing-breast-cancer-awareness-products-profitTo learn more about or donate to Michelle's Love: https://michelleslove.orgRATS theme song by Jessica BoudreauxTheme music by VyvyvyrJoin our Facebook group! Support us with Buy Me A Coffee or by rating, reviewing, and subscribing on Apple Podcasts (this seriously helps!)Donate to METAVIVOR!

Here's what is happening in the markets today, Monday, September 20th:- This morning index futures are getting hammered with the e-Mini DOW down 1.9%.- The overnight sell off picked up in China with the Hang Seng index down more than 3%.- A big concern in China is developer China Evergrande Group which is on brink of a default.- Pfizer (PFE) announced that trials show that their vaccine is safe in children ages 5-11.- Banks stocks down big pre-market following a drop in bond yields: BAC, WFC, JPM, and GS all down more than 3.0%.- AstraZeneca (AZN) up after announcing that their breast cancer drug Enhertu showed positive results in phase-three clinical trials. - Crude Oil taking a bit of a hit. Occidental Petroleum (OXY) is down 5% pre-market.If you enjoyed the "Stock Market Today" episode, make sure to subscribe to this podcast. And for more stock market news,  visit https://rockwelltrading.com.#todaysstockmarket #stockmarkettoday #stockmarket

This week's thought leaders include:Sara Hurvitz, MD, UCLA Jonsson Comprehensive Cancer CenterBrady Scott, PhD, Respiratory Care at Rush University Sallie McAdoo, Director of the Kidney Cancer AssociationDr. Medlaw, MD, JD, medical malpractice attorney, board certified radiologistIn a landmark case, a US jury has found a former police officer Derek Chauvin guilty of murder over the death of African-American George Floyd. From the medical point of view, one interesting and controversial aspect of this trial was of use of a video as evidence to prove the cause of death. In this episode of the Physician's Weekly Podcast, we spoke with our regular expert contributor with the pseudonym Dr. Medlaw about how videos can provide medical evidence for the murder of George Floyd.Also in this episode, we interview Dr. Brady Scott, Associate Professor in the Division of Respiratory Care at Rush University about Lessons learned in critical care / respiratory care during the COVID-19 pandemic.Medical Oncologist Sara Hurvitz, MD, at the UCLA Jonsson Comprehensive Cancer Center discusses a new clinical trial she is involved with taking a novel approach to treat breast cancer patients.But first we talk with the medical director of the Kidney Cancer Association, Sallie McAdoo, about the need for kidney cancer awareness in honor of World Kidney Cancer Day on June 17th, 2021.Let us know what you thought of this week's episode on Twitter: @physicianswkly Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com! Thanks for listening!

Drs. H. Jack West, Helena Yu and David Spigel discuss Enhertu and the Potential for Treatment of HER2 Positive NSCLC.

Enhertu (fam-trastuzumab deruxtecan-nxki) for locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma and received a prior trastuzumab-based regimen. Combination of Opdivo (nivolumab) + Cabometyx (cabozantinib) as first-line treatment for advanced renal cell carcinoma

Here are the links for everything discussed in Episode 50. Times are also below so feel free to skip around and get to the drugs that interest you. (1:14) Gemtesa approval for OAB (4:01) New indication for Enhertu (7:15) New monthly injectable treatment for HIV - Cabenuva and Vocabria CDC updates on COVID-19 & influenza reportingConnect with The Rx Daily Dose:Twitter      Instagram      YouTube      Linkedin       WebsiteEmail: therxdailydose@gmail.comConnect with Ian Parnigoni PharmD. on social media:Twitter       Instagram       Linkedin  ★ Support this podcast on Patreon ★

Here are the links for everything discussed in Episode 15. Approval of Ervebo for EVD Added indication for Lynparza Approval of Enhertu for HER2 positive breast cancer Ubrelvy approved to treat migraines in adults Approval of Dayvigo for insomnia Caplyta approved to treat schizophrenia in adults Connect with The Rx Daily Dose:Twitter      Instagram      YouTube      Linkedin       WebsiteEmail: therxdailydose@gmail.comConnect with Ian Parnigoni PharmD. on social media:Twitter       Instagram       Linkedin  ★ Support this podcast on Patreon ★